Peer

Assessment of the association between periodontal disease and total cancer incidence and mortality: a meta-analysis

Kaili Wang¹, Zheng Zhang^{2,3} and Zuomin Wang⁴

¹ Department of Stomatology, Beijing You 'an Hospital, Capital Medical University, Beijing, China

² Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin, China

³ Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction, Tianjin, China

⁴ Department of Stomatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

ABSTRACT

Background. Periodontal disease (PD) is a chronic inflammatory disease that leads to alveolar bone resorption and tooth loss. Many studies have reported the association between periodontal disease and various cancers including oral cancer, lung cancer, breast cancer and so on. However, there is still no specialized meta-analysis that assesses the association between periodontal disease and cancer incidence and mortality indeepth. Thus, we conducted this meta-analysis.

Methods. This meta-analysis was registered with PROSPERO: CRD42020183497. We searched five online databases for observational studies about the association between periodontal disease and breast, prostate, lung and bronchial, colorectal, and total cancers by July 2020. Then we evaluated quality of the included studies by the Newcastle-Ottawa scale. Risk ratios (HRs) and their 95% confidence intervals (CIs) were pooled to evaluate the strength of the association between periodontal disease and four cancers, total cancer incidence and mortality. In addition, we analyzed heterogeneity by subgroup analysis and sensitivity analysis. Finally, we inspected publication bias by Begg's and Egger's tests.

Results. None of the studies included in this meta-analysis were of poor quality. PD is not only related to breast cancer incidence (HR = 1.26,95%CI [1.11-1.43], $I^2 = 75.8\%$, P = 0.000), but also connected with total cancer mortality (HR = 1.40,95%CI [1.24-1.58], $I^2 = 0.0\%$, P = 0.718). Subgroup analyses showed that study population, study design, dental status, follow-up period, adjustment for smoking partially explained the heterogeneity between studies. The results of Begg's test and Egger's test were consistent and indicated that there is no publication bias in this study.

Conclusion. In conclusion, this meta-analysis revealed a positive relationship between periodontal disease and breast cancer incidence and total cancer mortality. Further well-designed studies with specific inclusion and exclusion criteria are required to strengthen the conclusion of this meta-analysis. However, longer follow-up period, multi-center trials and even multinational studies are required to corroborate the results.

Subjects Dentistry, Epidemiology, Global Health, Oncology Keywords Periodontal disease, Cancer, Incidence, Mortality, Meta-analysis

Submitted 18 May 2022 Accepted 9 October 2022 Published 7 November 2022

Corresponding authors Zheng Zhang, zhangzheng@nankai.edu.cn Zuomin Wang, wzuomin@sina.cn

Academic editor Adam Husein

Additional Information and Declarations can be found on page 19

DOI 10.7717/peerj.14320

Copyright 2022 Wang et al.

Distributed under Creative Commons CC-BY 4.0

OPEN ACCESS

INTRODUCTION

Periodontal disease is a chronic inflammatory disease that eventually leads to tooth loss. The initial factor associated with periodontal disease is dental plaque, which attacks the first immune defense line of periodontal tissue, leading to inflammation and disease. Periodontitis has a range of clinical manifestations, including gingiva bleeding, periodontal pocket, alveolar bone resorption, and tooth loss. Periodontitis is the major cause of tooth loss in adults. According to a National Health and Nutrition Examination survey, approximately 42% of American adults aged 30 years or older had periodontitis, with 7.8% having severe periodontitis (*Eke et al., 2018*). In Turkey, the proportion of individuals with more than three mm loss of attachment (LOA) ranged from 43% to 91% (*Ilhan et al., 2017*). In the Fourth National Oral Health Survey, the prevalence of probe bleeding in the 35 to 44-year-old population was 87.4% (*Sun et al., 2018*). There is a verified association between periodontal disease and a variety of diseases, such as rheumatoid arthritis (*Molon et al., 2019*), diabetes (*Genco & Borgnakke, 2020*), cardiovascular disease (*Sanz et al., 2020*), chronic obstructive pulmonary disease (*Takeuchi et al., 2019*), depression (*Nascimento et al., 2019*), and Alzheimer's disease (*Liccardo et al., 2020*).

Periodontitis is not only related to the abovementioned diseases but also to cancers. In recent years, an increasing number of studies have revealed the relationship between periodontal disease and various cancers, particularly head and neck (*Eliot et al., 2013*), esophageal (*Malinowski et al., 2019*), and pancreatic (*Fan et al., 2018*) cancers. Subsequently, researchers conducted meta-analyses of previous studies in order to reach a more accurate and objective conclusion. For example, *Yao et al. (2014)* reviewed five reliable studies, obtained data through the random effect model, and finally concluded that patients with periodontitis were prone to oral cancer. Six years later, *Gopinath et al. (2020)* analyzed nine studies and confirmed a significant correlation between periodontitis and head and neck cancer.

Cancer is not only difficult to overcome but also a heavy economic burden. In China (*Cao et al., 2020*), lung cancer remains the most common cancer and accounts for nearly 30% of cancer deaths. In 2015, the five cancers with the highest incidence included lung, stomach, colorectum, liver, and breast, accounting for nearly 60% of all diagnosed cancers. Every year, the American Cancer Society estimates the number of new cancer cases and cancer-related deaths in the population. According to recent data collected in 2019, prostate and lung & bronchial cancers were the two most common cancers in men, while, breast, lung, uterine corpus and colorectal cancers were the four most common cancers in women. The largest numbers of deaths result from lung, prostate, and colorectal cancers in men and lung, breast, and colorectal cancers in women (*Siegel, Miller & Jemal, 2019*).

In this context, we aimed to assess the correlations, in terms of incidence and mortality, between periodontal disease and cancers, including breast, prostate, lung and bronchial, colorectal, and total cancers, as well as the strength of these correlations. Furthermore, we aimed to preliminarily explore the factors that influence these correlations.

MATERIAL AND METHODS

Methodology

This meta-analysis was reported according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. The protocol was registered in PROSPERO (http://www.crd.york.ac.uk/PROSPERO) before the research was begun (CRD 42020183497).

Criteria for the inclusion of studies

The following criteria were applied: (1) studies published in English or Chinese; (2) studies on human subjects; (3) observational studies (including cohort and case-control studies) with a prospective or retrospective design; (4) studies with periodontal disease as the exposure and, the incidence or mortality associated with breast or prostate cancer, lung& bronchial or colorectal cancer, or total cancers as the outcome; and (5) studies providing relative risks (RRs), hazard ratios (HRs), or odds ratios (ORs) and corresponding 95% confidence intervals (CIs).

Literature search and selection

Databases: PubMed, Embase, Web of Science, China National Knowledge Infrastructure [CNKI] and Wanfang.

Search terms: (<Neoplasm= OR <Carcinoma= OR <cancer= OR <tumor= OR <tumour=) and (<periodontal diseases= OR <gum disease= OR <periodontitis= OR <gingivitis= OR <periodontal= OR <periodontium= OR <periodontal attachment loss= OR <periodontal pocket= OR <alveolar bone loss= OR <tooth mobility=). Time: by to July 2020.

First, two authors (Kaili Wang and Zheng Zhang) independently retrieved studies from the databases using specific search terms. Subsequently, a hand search was performed by reading abstracts and key words, and studies that were eligible for the inclusion criteria were selected. Finally, a consensus regarding the final studies to be included was reached *via* a discussion or by consulting a third author (Zuomin Wang).

Data extraction

Kaili Wang sorted out the information for the subsequent classification of the included studies: first author, publication date, country/region, study design type, numbers of samples, age range of the study population, diagnostic criteria for periodontal disease and cancer, cancer type and outcomes, follow-up period, whether adjustments were performed for smoking, adjusted variables, and multiple adjusted HRs and corresponding 95% CIs. Next, Zheng Zhang checked the information and supplemented it if necessary.

Quality assessment

We evaluated the quality of the included studies using the Newcastle-Ottawa scale. This evaluation system includes three aspects: selection, comparability and exposure. In the selection part, we evaluated the following four aspects: whether the exposed cohort could basically represent the average of the community population, whether the non-exposed cohort was from the same source as the exposure cohort, whether the selection of the

exposed cohort was reliable based on records, and whether no outcome events occurred in the study subjects before the study began. In the comparability part, we assessed whether the exposed and non-exposed cohorts were matched in terms of age and other confounding factors. In the exposure part, we assessed the following three aspects: whether there were reliable data or records, such as examination or medical records, for the evaluation of outcome events; whether the follow-up period was equal to or longer than 5 years; and the completeness of follow-up through factors, such as the loss to follow-up rate.

Based on the scores, the studies were defined as follows: <4 points, low quality; 4–6 points, moderate quality; and 7–9 points, high quality.

Classification of studies

First, the included studies were classified according to the study scope: breast, prostate, lung & bronchial, colon & Rectum, and total cancers. Next, according to the specific content and purpose of the studies, we divided them based on two aspects: cancer occurrence and cancer mortality. Of course, som studies involved both incidence and mortality.

Statistical analysis

We used the HR with the 95% CI to assess the association between periodontal disease and the risk of cancer incidence and mortality. The data extracted from the studies were analyzed using STATA software (version 12.0; Stata Corp, College Station, TX, USA). Heterogeneity was tested through the Q test (statistical significance was set at P < 0.1) and I^2 test (I $^2 \ge 50\%$ indicated significant heterogeneity) and was represented using a forest plot.

Subgroup analyses were conducted to explore the factors influencing heterogeneity. Subgroup analyses were stratified by study population, study design, dental status, followup period, and whether or not smoking was adjusted for. A sensitivity analysis was performed to test the stability of the results.

Begg's and Egger's tests were used for assessing publication bias. Begg's test, also known as the rank correlation test, tests the correlation between effects and sample size. Egger's test, also known as the linear regression method, establishes a regression equation based on the standard normal deviate and precision of each included study. The larger the intercept of the regression line, the higher the bias. A *P*-value of > 0.05 was considered to indicate no publication bias..

RESULTS

Search and selection results

The process of study selection is shown in Fig. 1. First, 3,324 records were collected from PubMed, 5,681 from Embase, 5,435 from Web of Science, 1,095 from Wanfang, and 1,576 from CNKI. Subsequently, 9,860 publications remained after the duplicates were removed, of which 72 were deemed eligible based on their abstracts and key words. Finally, 27 publications were included in the meta-analysis after 45 studies were excluded for several reasons. Duplicates were removed for the following reasons: review/commentary/letter (n = 13), repeat publication (n = 7), no available data (n = 22), and no full text (n = 3).




Figure 1 Flow chart from identification of eligible studies to final inclusion. Full-size DOI: 10.7717/peerj.14320/fig-1

Characteristics of the included studies

Table 1 describes the studies included in the review. The articles were published between2003 and 2020. Twelve studies were conducted in North America and six in China.Six studies were retrospective, and the others were prospective. Periodontal disease wasdiagnosed through a dental examination in 18 studies (*Hujoel et al., 2003; Ahn, Segers*& Hayes, 2012; Wen et al., 2014; Chrysanthakopoulos, 2016; Chung et al., 2016; Mai etal., 2016; Dizdar et al., 2017; Han, 2017; Lee et al., 2017; Sfreddo et al., 2017; Chou et al.,2018; Heikkilä et al., 2018; Hu et al., 2018; Michaud et al., 2018; Güven et al., 2019; Lu et al.,2019; Tai et al., 2019; Huang et al., 2020), among which the International Classificationof Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) was used in five studies

(Wen et al., 2014; Chung et al., 2016; Chou et al., 2018; Hu et al., 2018; Tai et al., 2019), and the definition criteria of periodontal pocket and attachment loss were used in 13 studies (Hujoel et al., 2003; Ahn, Segers & Hayes, 2012; Chrysanthakopoulos, 2016; Mai et al., 2016; Dizdar et al., 2017; Han, 2017; Lee et al., 2017; Sfreddo et al., 2017; Heikkilä et al., 2018; Michaud et al., 2018; Güven et al., 2019; Lu et al., 2019; Huang et al., 2020). The diagnosis was self-reported by patients based on questionnaires and tooth loss history in the remaining nine studies (Michaud et al., 2008; Arora et al., 2010; Mai et al., 2014; Freudenheim et al., 2016; Michaud et al., 2016; Momen-Heravi et al., 2017; Nwizu et al., 2017; Lee et al., 2018; Yoon et al., 2019), among which dentists validated the diagnosis in three studies (Michaud et al., 2016; Momen-Heravi et al., 2017; Lee et al., 2018). Six studies analyzed periodontal disease and cancer mortality (Hujoel et al., 2003; Ahn, Segers & Hayes, 2012; Mai et al., 2014; Heikkilä et al., 2018; Lu et al., 2019; Huang et al., 2020), and 22 studies analyzed periodontal disease and cancer incidence (Michaud et al., 2008; Arora et al., 2010; Wen et al., 2014; Chrysanthakopoulos, 2016; Chung et al., 2016; Freudenheim et al., 2016; Mai et al., 2016; Michaud et al., 2016; Dizdar et al., 2017; Han, 2017; Lee et al., 2017; Momen-Heravi et al., 2017; Nwizu et al., 2017; Sfreddo et al., 2017; Chou et al., 2018; Hu et al., 2018; Lee et al., 2018; Michaud et al., 2018; Güven et al., 2019; Lu et al., 2019; Tai et al., 2019; Yoon et al., 2019). Cancer diagnosis was based on ICD-9/10-CM in 15 studies (Hujoel et al., 2003; Arora et al., 2010; Ahn, Segers & Hayes, 2012; Mai et al., 2014; Wen et al., 2014; Chung et al., 2016; Lee et al., 2017; Momen-Heravi et al., 2017; Nwizu et al., 2017; Sfreddo et al., 2017; Chou et al., 2018; Heikkilä et al., 2018; Hu et al., 2018; Tai et al., 2019; Yoon et al., 2019), medical records and histological examination in 11 studies (*Michaud et al., 2008*; Chrysanthakopoulos, 2016; Freudenheim et al., 2016; Mai et al., 2016; Michaud et al., 2016; Dizdar et al., 2017; Lee et al., 2018; Michaud et al., 2018; Güven et al., 2019; Lu et al., 2019; Huang et al., 2020), and patient self-report in 1 study (Han, 2017). All the participants were aged above 18 years, and the follow-up period was more than 10 years in 15 studies (Hujoel et al., 2003; Michaud et al., 2008; Arora et al., 2010; Ahn, Segers & Hayes, 2012; Wen et al., 2014; Mai et al., 2016; Michaud et al., 2016; Dizdar et al., 2017; Lee et al., 2017; Momen-Heravi et al., 2017; Chou et al., 2018; Heikkilä et al., 2018; Michaud et al., 2018; Tai et al., 2019; Huang et al., 2020) and less than 10 years in 12 studies (Mai et al., 2014; Chrysanthakopoulos, 2016; Chung et al., 2016; Freudenheim et al., 2016; Han, 2017; Nwizu et al., 2017; Sfreddo et al., 2017; Hu et al., 2018; Lee et al., 2018; Güven et al., 2019; Lu et al., 2019; Yoon et al., 2019). Most studies collected information on whether the participants smoked, including how often and how much they smoked and the pack-years. Regarding smoking, eight studies (Wen et al., 2014; Chung et al., 2016; Dizdar et al., 2017; Chou et al., 2018; Heikkilä et al., 2018; Hu et al., 2018; Güven et al., 2019; Tai et al., 2019) did not perform adjustments for smoking; however, the remaining studies included smokers and took smoking into account when calculating the HRs.

Quality assessment

Table S1 shows the quality assessment of the included studies. Twenty-four studies scored seven or more stars, indicating that 88.9% of the studies were of good quality.

Table 1 Characteristics of eligible studies included in this meta-analysis.

Author (Year)	Location	Study design	Participants number	Age (years)	Dental status	Outcomes	Cancer type	Assessment method	Follow-up (year)	Adjusted variables
Hujoel et al. 2003	USA	Prospective study	11,328	25–74	Dental examination	Cancer mortality	breast, prostate, lung & bronchus, colon & rectum, total cancer	ICD-9	18	age, gender, educa- tion, socioeconomic level, race, smoking, alcohol consumption, vitamin consumption et al.
Michaud et al. 2008	USA	Prospective study	48,375	40–75	Self-reported	Cancer incidence	prostate, lung & bronchus, colon & rectum, total cancer	Medical records or histological examina- tion	17.7	age, race, smoking, alcohol consumption, vitamin consumption body mass index, di- abetes, physical activ- ity, et al.
Arora et al. 2010	Swedish	Prospective study	15,333	38–77	Self-reported	Cancer incidence	breast, prostate, colon & rectum, total cancer	ICD	27	age, gender, educa- tion, smoking, alcohol consumption, body mass index, diabetes, et al.
Ahn et al. 2012	USA	Prospective study	12,605	≥17	Dental examination	Cancer mortality	colon & rectum	ICD-10	12	age, gender, educa- tion, race, smoking, body mass index, et al.
Mai et al. 2014	USA	Prospective study	77,485	50–79	Self-reported	Cancer mortality	lung & bronchus	ICD-O-2	6.8	age, education, race, smoking, alcohol con- sumption, body mass index, physical activ- ity, et al.
Wen et al. 2014	China	Prospective study	1 million	>20	Dental examination	Cancer incidence	breast, lung & bronchus, total can- cer	ICD-9	14	age, gender, et al.
Chrysanthakopoulos et al. 2016	Greek	Retrospective study	200	≥48	Dental examination	Cancer incidence	lung & bronchus	Medical records or histological examina- tion	2	age, gender, educa- tion, socioeconomic level, smoking, et al.
Chung et al. 2016	China	Prospective study	40,140	≥ 40	Dental examination	Cancer incidence	breast, total cancer	ICD-9	5	socioeconomic level, diabetes, et al.
Freudenheim et al. 2016	USA	Prospective study	73,737	50–79	Self-reported	Cancer incidence	breast	Medical records or histological examina- tion	6.7	age, education, race, smoking, alcohol con- sumption, body mass index, physical activ- ity, et al.
Mai et al. 2016	China	Prospective study	1,337	53-85	Dental examination	Cancer incidence	breast, lung & bronchus, colon & rectum, total cancer	Medical records or histological examina- tion	12.2	age, smoking, et al.
Michaud et al. 2016	USA	Prospective study	19,933	40-75	Self-reported	Cancer incidence	prostate, lung & bronchus, colon & rectum, total cancer	Medical records or histological examina- tion	26	age, race, smoking, alcohol consumption, body mass index, di- abetes, physical activ- ity, et al.
Dizdar et al. 2017	Turkey	Prospective study	280	≥35	Dental examination	Cancer incidence	breast, prostate, lung & bronchus, total cancer	Medical records or histological examina- tion	12	age, gender, et al.
Han et al. 2017	Korea	Retrospective study	22,948	≥19	Dental examination	Cancer incidence	breast, lung & bronchus, colon & rectum, total cancer	self-reported	2	education, socioeco- nomic level, smoking, alcohol consumption, et al.
Lee et al. 2017	Korea	Prospective study	934	≥40	Dental examination	Cancer incidence	prostate, colon & rectum	ICD-10	12	age, gender, socioeco- nomic level, smoking, alcohol consumption, diabetes, physical ac- tivity, et al. nued on next page

Table 1 (continued)

Author (Year)	Location	Study design	Participants number	Age (years)	Dental status	Outcomes	Cancer type	Assessment method	Follow-up (year)	Adjusted variables
Momen-Heravi et al. 2017	USA	Prospective study	121,700	30–55	Self-reported	Cancer incidence	colon & rectum	ICD-9	19	age, race, smoking, alcohol consumption vitamin consumptio body mass index, dia betes, et al.
Nwizu1 et al. 2017	USA	Prospective study	65,869	54-86	Self-reported	Cancer incidence	breast, lung & bronchus, colon & rectum, total cancer	ICD or Medical records	8.32	age, smoking, body mass index, et al.
Sfreddo et al. 2017	Brazil	Retrospective study	201	≥ 18	Dental examination	Cancer incidence	breast	ICD-10 or Medical records	2.2	age, smoking, body mass index, et al.
Chou et al. 2018	China	Retrospective study	67,672	≥18	Dental examination	Cancer incidence	colon & rectum	ICD-9	10	age, gender, educa- tion, socioeconomic level, diabetes, et al.
Heikkilä et al. 2018	Finland	Prospective study	68,273	≥29	Dental examination	Cancer mortality	breast, prostate, lung & bronchus, total cancer	ICD-10	10.1	age, gender, socioec nomic level, diabete et al.
Hu et al. 2018	China	Prospective study	212,974	$\geq \! 18$	Dental examination	Cancer incidence	colon & rectum	ICD-9	3	age, gender, et al.
Lee et al. 2018	Korea	Retrospective study	42,871	30-45	Self-reported	Cancer incidence	colon & rectum	Medical records or histological examina- tion	3	age,sex,BMI, DM, HbA1c, HTN, LDL ,waist,alcohol in- take,smoking status and pack-years.
Michaud et al. 2018	USA	Prospective study	7,466	44-66	Dental examination	Cancer incidence	breast, prostate, lung & bronchus, colon & rectum, total cancer	Medical records or histological examina- tion	14.7	age, field center, edu cation level, smokin status, smoking dur tion, drinking status body mass index, ar diabetes status
Güven et al. 2019	Turkey	Prospective study	5,199	≥50	Dental examination	Cancer incidence	lung & bronchus, colon & rectum, total cancer	Medical records or histological examina- tion	7.2	age, gender, et al.
Lu et al. 2019	USA	Prospective study	15,792	44-66	Dental examination	Cancer incidence and mortality	Lung & bronchus, colon & rectum, total cancer	Medical records or histological examina- tion	4	age, education, race smoking, alcohol co sumption, diabetes, al.
Tai et al. 2019	China	Prospective study	714,246	No metion	Dental examination	Cancer incidence	lung & bronchus	ICD-9	≥10	no
Yoon et al. 2019	USA	Retrospective study	84,797	40–79	Self-reported	Cancer incidence	lung & bronchus	ICD-10	8	education, socioeco nomic level, smokir alcohol consumptio body mass index, et al.
Huang et al. 2020	USA	Prospective study	6,034	≥40	Dental examination	Cancer mortality	total cancer	Medical records or histological examina- tion	21.3	age, gender, educa- tion, socioeconomi level, race, smoking body mass index, di abetes, et al.

Notes.

ICD: International Classification of Diseases.

Association between periodontitis and cancer incidence

The relationship between periodontal disease and cancer incidence is shown in Fig. 2. The pooled estimate based on 11 studies revealed a modest association between periodontal disease and breast cancer incidence (HR = 1.26, 95% CI [1.11–1.43]), with greater heterogeneity ($I^2 = 75.8\%$, $P_Q = 0.000$). Similarly, we found a modest association between periodontal disease and prostate (HR = 1.26, 95% CI [1.03–1.54], $I^2 = 72.9\%$, $P_Q = 0.001$), lung & bronchus (HR = 1.30, 95% CI [1.13–1.50], $I^2 = 63.7\%$, $P_Q = 0.000$), colon & rectum (HR = 1.18, 95% CI [1.03–1.36], $I^2 = 79.0\%$, $P_Q = 0.000$), and total (HR = 1.14, 95% CI [1.08–1.20], $I^2 = 67.4\%$, $P_Q = 0.000$)cancer incidence.

Next, we explored the source of heterogeneity through subgroup analyses with $I^2 > 50\%$ and P < 0.1.

Sensitivity analyses of the association between periodontitis and cancer incidence

As shown in Fig. 3, the pooled HRs were the same, and the 95%CI overlapped with the previous effect size. This means that our results are very reliable.

Subgroup analyses of the association between periodontitis and cancer incidence

The subgroup analysis results are presented in Table 2.

The following were the observations regarding the 11 studies that were conducted on periodontal disease and breast cancer incidence. Four studies were from North America and showed an HR of 1.12 ($I^2 = 0\%$, 95% CI [1.05–1.19], P = 0.001). Two studies were retrospective and showed an HR of 1.52 ($I^2 = 0\%$, 95% CI [1.17–1.98], P = 0.002). The pooled HR in four studies in which the periodontal disease diagnosis was self-reported was 1.15 ($I^2 = 0\%$, 95% CI [1.09–1.22], P = 0.001). Six studies with follow-up periods of more than 10 years showed an HR of 1.11($I^2 = 14.4\%$, 95% CI [1.03–1.19], P = 0.005). The pooled HR in seven studies in which smoking was adjusted for was 1.13 ($I^2 = 7.7\%$, 95% CI [1.07–1.21], P = 0.001). The CIs were all on the right side. The results of the subgroup analyses were consistent with those of the full dataset analysis. We can state with certainty that periodontal disease increases the risk of breast cancer incidence.

The following were the observations in the seven studies on periodontal disease and prostate cancer incidence. Three studies were from North America and showed an HR of 1.03 ($I^2 = 36.9\%$, 95% CI [0.89–1.18], P = 0.728). Six studies with follow-up periods of more than 10 years showed an HR of 1.16 ($I^2 = 60.8\%$, 95% CI [0.97–1.38], P = 0.100).We found that periodontal disease increased the risk of prostate cancer incidence under certain conditions in the European people, dental examination diagnosis of periodontal disease, follow-up period of less than 10 years. However, the association was not affected by smoking.

Among the 14 studies on periodontal disease and lung and bronchial cancer incidence, eight studies were from North America and showed an HR of 1.34 ($I^2 = 46.9$, 95% CI [1.24–1.46], P = 0.001), and eight studies in which periodontal disease was diagnosed through dental examination showed an HR of 1.33 ($I^2 = 75.7$, 95% CI [0.94–1.88],

Streads (2017) Michael (2018) Given (2019) 135 (1.14, 2.11) 8.42 (2.19 (1.72, 2.71) 8.72 (2.19 (1.72, 2.72) 8.72 (2.19 (1.72, 2.72) 8.72 (2.19 (1.72, 2.72) 8.72 (2.19 (1.72, 2.72) 8.72 (2.19 (1.11, 2.13) 1.24 (1.10, 2.13) 1.24 (1.10, 2.13) 1.24 (1.11, 2.13)	Study, first author (year)	HR (95% CI)	Weight, %
Acca (2016) 112 (0.75, 16.9) 6.21 Chung (2016) 1.23 (1.11, 1.23) 1.33 Mac (2016) 1.23 (1.11, 1.23) 1.33 Mac (2016) 1.23 (1.11, 1.23) 1.33 Mac (2017) 1.34 (1.24, 1.21) 8.24 Mac (2017) 1.35 (1.24, 1.21) 8.24 Mac (2017) 1.35 (1.24, 1.21) 8.24 Mac (2017) 1.35 (1.31, 1.23) 1.32 Mac (2017) 1.35 (1.31, 1.23) 1.32 Machaud (2018) 0.36 (0.72, 1.10) 1.77 Acca (2016) 1.47 (1.04, 2.07) 1.33 Machaud (2008) 0.36 (0.72, 1.10) 1.77 Acca (2017) 1.44 (1.38, 2.40) 1.46 Machaud (2008) 1.16 (0.77, 1.50) 1.35 Govern (1977) 1.44 (1.38, 2.40) 1.46 Machaud (2008) 1.16 (0.78, 1.50) 1.35 Machaud (2018) 1.36 (1.16, 1.60) 1.23 Machaud (2018) 1.26 (1.01, 1.54) 1.26 (1.01, 1.54) Machaud (2018) 1.25 (1.01, 1.27) 1.24 (1.02, 1.27) <tr< td=""><td>Breast</td><td></td><td></td></tr<>	Breast		
Wen (2014) 1.64 (0.00, 1.20) 1.38 (0.11, 1.38) 1.38 (0.1		4 40 /0 75 4 00	6.04
Chung (2016) Prostacteriser (2016) Hang (2017) Hang (2018) Chernel (# * 72.5%, p.g. = 0.000) Prostate Prostate Hang (2018) Chernel (# 77.25%, p.g. = 0.000) Hang (2018) Chernel (# 197.25%, p.g. = 0.000) Hang (2018) Hang (2018)			
Feudemenin (2019) 1.11 (10.0.12.0) 15.32 Mac (2017) 2.40 (10.8.12.0) 15.32 News(2017) 1.35 (10.8.12.0) 15.32 News(2017) 1.55 (1.4.2.13) 15.32 News(2017) 1.55 (1.4.2.13) 15.32 News(2017) 1.55 (1.4.2.13) 15.32 News(2017) 1.55 (1.4.2.13) 10.72 News(2017) 1.56 (1.4.2.13) 10.72 News(2017) 1.56 (1.4.2.13) 10.73 News(2017) 1.57 (1.4.2.13) 10.73 News(2017) 1.77 (0.8.3.147) 12.80 Netword (2016) 1.77 (0.8.3.147) 12.80 Netword (2016) 1.77 (0.8.3.147) 12.80 Netword (2016) 1.84 (1.6.3.2.409) 14.81 Netword (2016) 1.84 (1.6.3.2.409) 14.92 Netword (2016) 1.84 (1.6.3.2.409) 14.92 Netword (2016) 1.84 (1.6.3.2.409) 12.81 Netwo			
Mail (2019) 049 (0.04, 15.3) 2.20 Han (2017) 140 (0.06, 5.33) 2.20 Han (2017) 154 (0.06, 5.33) 2.20 Methods (2019) 0.04 (0.06, 1.33) 1.35 Obver (2019) 0.04 (0.06, 1.33) 2.20 Methods (2019) 0.04 (0.06, 1.34) 4.24 Methods (2019) 0.04 (0.06, 1.34) 4.24 Overall (* 7.5 9%, p.g. = 0.000) 1.07 (0.1, 2.07) 1.35 Prostate 0.94 (0.72, 1.10) 1.77 (0.83, 1.47) 1.20 Methods (2019) 1.47 (0.16, 2.30) 1.47 (0.16, 2.34) 1.32 Methods (2019) 1.47 (0.16, 2.34) 1.32 1.35 (1.36, 1.34) 1.30 Datair (2017) 1.56 (1.51, 1.44) 1.30 1.35 (1.36, 1.34) 1.30 Overall (* - 72.9%, p.g. = 0.001) 1.36 (1.16, 1.60) 1.23 (1.36, 1.54) 1.25 (1.36, 1.40) 1.23 (1.36, 1.40) 1.23 (1.36, 1.40) 1.23 (1.36, 1.40) 1.24 (1.32, 2.44) 1.44 (0.96, 1.31) 1.26 (1.06, 1.40) 1.23 (1.36, 1.40) 1.24 (1.32, 2.44) 1.44 (0.96, 1.31) 1.26 (1.06, 1.40) 1.25 (1.06, 1.40) 1.25 (1.06, 1.40) 1.25 (1.06, 1.40) 1.25 (1.06, 1.40) 1.25 (1.06, 1.4			
Dataser (2017) 1.4 (6.068, 2.41) 4.41 Name, (2017) 1.43 (0.08, 2.41) 4.42 Ober, (2019) 2.19 (1.72, 2.77) 10.75 Ober, (2019) 1.24 (1.11, 1.43) 1000 Overall (* 7.58.K.p. = 0.000) 1.47 (1.04, 2.07) 13.33 Ober, (2017) 1.43 (1.11, 1.43) 1000 Nethand (2016) 1.47 (1.04, 2.07) 13.33 Given (2017) 1.44 (1.08, 1.49) 14.55 (1.08, 1.49) 14.55 (1.08, 1.49) Michand (2016) 1.56 (1.08, 1.49) 1.25 (1.08, 1.49) 1.26 (1.11, 1.43) Michand (2016) 1.56 (1.08, 1.49) 1.25 (1.08, 1.49) 1.26 (1.11, 1.43) Michand (2016) 1.56 (1.08, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.49) Michand (2016) 1.56 (1.08, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.49) 1.26 (1.16, 1.29) 1.28 (1.16, 1.29) 1.26 (
Han (207) 1.45 (0.88, 2.3) 4.55 Steade (207) 1.53 (1.64, 2.3) 1.53 Overall (F = 75.8%, p ₀ = 0.000) 1.67, 72, 710 1.07 Prostate 0.69 (0.72, 1.10) 1.72 Mchaud (2016) 1.44 (0.69, 1.31) 2.20 Coloren (2019) 1.44 (0.69, 1.31) 2.20 Datar (2016) 1.36 (1.64, 1.52) 1.58 Coloren (2019) 1.44 (0.69, 1.31) 2.20 Oction (2019) 1.36 (1.64, 1.60) 1.23 Oction (2016) 1.38 (1.64, 1.60) 1.23 Methaud (2017) 1.38 (1.64, 1.60) 1.23 Methaud (2017) 1.38 (1.64, 1.60) 1.23			
Streads (2017) Methand (2018) Owent (1* 7558), p. = 0.000) 1.15 (1.16, 1.15) 8.24 (0.46, 1.43) 4.26 (0.46, 1.43) Owent (1* 7558), p. = 0.000) 1.28 (1.11, 1.13) 1000 Prostaite 0.28 (0.72, 1.16) 1.77 (0.03, 1.77) Mehand (2018) 0.28 (0.72, 1.16) 1.77 (0.03, 1.77) Mehand (2018) 0.28 (0.72, 1.16) 1.77 (0.03, 1.77) Distair (2017) 1.77 (0.03, 1.77) 1.33 (1.16, 1.50) 1.33 (1.16, 1.50) Mehand (2018) 1.38 (1.16, 1.50) 1.33 (1.16, 1.54) 10.00 Covent (1* 72, 25%, p. = 0.001) 1.38 (1.16, 1.56) 1.38 (1.16, 1.56) 1.38 (1.16, 1.56) Mehand (2018) 1.38 (1.16, 1.56) 1.38 (1.16, 1.57) 1.24 (1.56, 2.21) 2.23 (1.77, 12, 22) Mehand (2018) 1.38 (1.16, 1.57) 1.24 (1.56, 2.31) 2.22 (1.77, 12, 12, 22) Mehand (2018) 1.38 (1.16, 1.57) 1.24 (1.56, 2.31) 2.22 (1.77, 12, 12, 22) Mehand (2018) 1.38 (1.16, 1.57) 1.24 (1.16, 1.57) 1.24 (1.16, 1.57) Mehand (2018) 1.38 (1.16, 1.57) 1.24 (1.16, 1.57) 1.24 (1.16, 1.57) Mehand (2018) 1.38 (1.16, 1.57)<			4.61
Methand (2016) 0.04 (0.49, 1.43) 4.26 <t< td=""><td>Nwizu (2017)</td><td>1.13 (1.04, 1.23)</td><td>15.82</td></t<>	Nwizu (2017)	1.13 (1.04, 1.23)	15.82
Glown (2019) 2.19 (173, 277) 107.57 Nethaud (2016) 1.28 (1.11, 1.43) 1000 Michaud (2016) 0.89 (0.72, 1.10) 1.77 Arcra (2010) 1.47 (1.04, 2.07) 13.37 Michaud (2016) 1.77 (1.03, 1.47) 13.29 Dama (C) (71) 1.44 (1.53, 2.49) 14.49 Nethaud (2016) 1.26 (1.11, 1.43) 1000 Oxeral (F = 72.9K, p. e 0.001) 1.38 (1.46, 1.60) 12.31 Nethaud (2016) 1.38 (1.46, 1.60) 12.31 Michaud (2017) 1.38 (1.46, 1.60) 12.31 Nam (2014) 1.38 (1.46, 1.60) 12.31 Michaud (2017) 1.38 (1.46, 1.60) 12.31 Nam (2017) 1.38 (1.46, 1.60) 12.31 Nam (2017) 1.38 (1.46, 1.50) 12.33 Nam (2017) 1.38 (1.46, 1.50) 12.31 Nam (2017) 1.38 (1.46, 1.30) 3.41	Sfreddo (2017)		
Overall (** 75.8%, p. = 0.000) 1.26 (1.11, 1.43) 1000 Mohad (2069) 0.89 (0.72, 1.10) 1.77 Arona (2010) 1.47 (1.04, 2.07) 13.33 Mohad (2016) 1.77 (0.31, 1.47) 17.20 Mohad (2016) 1.36 (1.16, 1.60) 13.47 Science (77) 1.48 (1.33, 2.49) 13.53 Mohad (2016) 1.36 (1.16, 1.60) 1.26 (1.13, 1.64) Overall (* 7.2.9%, p. = 0.001) 1.26 (1.16, 1.60) 1.26 (1.13, 1.64) Mohad (2016) 1.36 (1.16, 1.60) 1.26 (1.13, 1.64) 1.00 Mohad (2016) 1.36 (1.16, 1.60) 1.26 (1.11, 1.43) 1.00 Mohad (2016) 1.36 (1.16, 1.60) 1.26 (1.17, 1.33) 1.44 (1.20, 1.20) 1.26 (1.11, 1.43) 1.00 Mohad (2016) 1.36 (1.16, 1.50) 1.26 (1.11, 1.43) 1.00 1.26 (1.11, 1.43) 1.00 Mohad (2016) 1.36 (1.16, 1.50) 1.26 (1.11, 1.43) 1.00 1.26 (1.11, 1.43) 1.00 Mohad (2017) 1.26 (1.11, 1.43) 1.16 (1.11, 1.17) 1.24 1.17 (1.16, 1.16) 1.17 (1.16, 1.16) 1.17 (1.16, 1.16)			
Prostate Michaud (2016) Aren (2017) Lac (2017) Lac (2017) Lac (2017) Lac (2017) Lac (2017) Lac (2017) Lac (2017) Lac (2018) Goven (2019) Datas (2016) Lac (2017) Lac (120) Covent (2 ¹ = 72.5%, p ₀ = 0.001) Lung & bronchus Michaud (2016) Lung & bronchus Michaud (2016) Lag (156, 1.40) Lag (157, 1.41) Lag (156, 1.40) Lag (157, 1.42) Lag (157, 1.44) Han (2017) Michaud (2016) Govent (1 ¹ = 72.5%, p ₀ = 0.000) Covent (1 ¹ = 70.5%, p ₀ =			
Methad (2069) Aron (2010) 0.89 (072, 110) 17, 203, 147) Methad (2016) 1.77 (033, 147) 17.20 Disdir (2017) 1.49 (134, 2.07) 3.34 Lee (2017) 1.49 (134, 2.07) 3.34 Lee (2017) 1.49 (134, 2.07) 1.38 (115, 1.40) 12.30 Ownerll (* 7.25%, p.g. 0.001) 1.26 (103, 1.54) 1.30 (115, 1.60) 12.31 Uming & Dronchus 1.38 (115, 1.60) 12.31 1.48 (135, 2.49) 14.67 Michaud (2016) 1.39 (115, 1.60) 12.31 1.22 (105, 1.48) 12.51 Michaud (2016) 1.59 (109, 2.31) 7.22 Michaud (2016) 1.59 (109, 2.31) 7.22 Michaud (2016) 1.59 (109, 2.31) 7.22 Michaud (2017) 3.44 1.33 (114, 1.51) 12.44 Michaud (2016) 1.59 (109, 2.31) 7.22 Michaud (2017) 1.33 (114, 1.51) 12.44 1.33 (114, 1.51) 12.44 1.33 (114, 1.51) 12.44 1.33 (114, 1.51) 12.44 1.33 (114, 1.51) 12.44 1.33 (114, 1.51) 12.56 1.33 (116, 1.45) 1.33 (116, 1.45) 1.33 (116, 1.45) 1.33 (116, 1.45) 1.33 (116, 1.45) 1.44 (127, 122) <td< td=""><td>Overall ($P = 75.8\%$, $p_0 = 0.000$)</td><td>1.26 (1.11, 1.43)</td><td>100.00</td></td<>	Overall ($P = 75.8\%$, $p_0 = 0.000$)	1.26 (1.11, 1.43)	100.00
Mohad (2016) 0.89 (072, 100) 17, 203, 147) Mohad (2016) 1.77 (134, 147) 17.20 Dadar (2017) 1.71 (035, 147) 17.20 Lee (2017) 1.41 (0.97, 1.54) 1.38 (137, 133) 2007 Michaud (2016) 1.26 (103, 1.54) 1.38 (116, 1.60) 1.38 (116, 1.60) 1.38 (116, 1.60) 1.38 (116, 1.60) 1.38 (116, 1.60) 1.38 (116, 1.60) 1.38 (116, 1.60) 1.23 (106, 1.48) 1.26 (103, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1.26 (113, 1.54) 1	Prostate		
Acora (2010) 1.477 (10.42, 207) 13.38 Michaud (2016) 3.75 (13.8, 10.21) 3.34 Lee (2017) 1.44 (10.89, 13.31) 20.20 Michaud (2018) 1.10 (07.8, 15.9) 13.58 Golven (2019) 1.26 (13.6, 16.9) 13.58 Overall (* 7.2.9%, p. = 0.001) 1.26 (13.6, 16.9) 12.33 America (2016) 1.28 (13.6, 14.9) 12.33 Michaud (2016) 1.28 (13.6, 14.9) 12.33 Michaud (2016) 1.28 (13.6, 14.9) 12.33 Chynamhukopolos (2016) 1.28 (13.6, 14.9) 12.33 Michaud (2016) 1.28 (13.6, 14.9) 12.33 Chynamhukopolos (2016) 1.28 (13.6, 14.9) 12.33 Michaud (2016) 1.28 (13.6, 14.9) 12.33 Ochan (2017) 1.38 (13.6, 14.9) 12.33 Han (2017) 1.38 (13.6, 14.9) 12.33 Michaud (2018) 0.22 (14.4, 1.39) 4.39 Gloven(Mein (2019) 1.31 (1.14, 1.59) 100.01 Chynamhukopolos (2019) 1.33 (13.6, 14.9) 1.33 (13.6, 14.9) Michaud (2016) 1.33 (13.8, 13.9) 1.36 Chynamhukopol		0.89 (0.72, 1.10)	17.76
Mehadu (2016) 1.17 (203, 1.47) 17.20 Dodar (2017) 3.75 (1.38, 10.23) 3.37 (1.38, 10.24) Lee (2017) 1.14 (108, 1.31) 20.07 Mehadu (2018) 1.14 (108, 1.34) 1.15 (1.08, 1.49) 1.15 (1.08, 1.49) Güven (2019) 1.24 (1.18, 2.49) 1.46 (1.06, 1.49) 1.23 (1.08, 1.49) 1.20 (1.08, 1.49) Mehadu (2016) 1.36 (1.16, 1.60) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.08, 1.49) 1.23 (1.18, 1.59) 1.24 (1.02, 2.19) 1.24 (1.02, 2.19) 1.23 (1.14, 1.59) 1.26 (1.14, 1.59)			
Dadar (2017) Lee (2017) Mehaud (2018) Gowen (2019) Overall (* 7.2.9%, p., = 0.001) Mehaud (2006) Mai (2014) Chrysenhakopoulos (2016) Chrysenhakopoulos (2016) Mehaud (2016) Mehaud (2016) Mehaud (2016) Mehaud (2017) Han (2017) Mehaud (2016) Mehaud (2017) Mehaud (2017) Mehaud (2017) Mehaud (2019) Coverall (* = 53.7%, p., = 0.000) Colo & rectum Mehaud (2018) Mehaud (2018) Mehaud (2019) Coverall (* = 53.7%, p., = 0.000) Colo & rectum Mehaud (2018) Mehaud (2019) Coverall (* = 53.7%, p., = 0.000) Colo & rectum Mehaud (2018) Mehaud (2019) Coverall (* = 53.7%, p., = 0.000) Colo & rectum Mehaud (2018) Mehaud (2019) Coverall (* = 53.7%, p., = 0.000) Colo & rectum Mehaud (2018) Mehaud (2019) Coverall (* = 53.7%, p., = 0.000) Colo & rectum Mehaud (2018) Mehaud (2018) Mehaud (2018) Mehaud (2018) Mehaud (2018) Mehaud (2018) Mehaud (2019) Colo & rectum Mehaud (2018) Mehaud (2019) Colo & Crectum Mehaud (2019) Colo & Crectum Mehaud (2018) Mehaud (2019) Colo & Crectum Mehaud (2018) Mehaud (2019) Colo & Crectum Mehaud (2018) Mehaud (2019) Colo & Crectum Mehaud (2018) Mehaud (2018) Mehaud (2018) Mehaud (2019) Colo & Crectum Mehaud (2018) Mehaud (2019) Colo & Crectum Mehaud (2018) Mehaud (2019) Mehaud (2019) Mehaud (2019) Mehaud (2019) Mehaud (2019) Mehaud (2018) Mehaud (2019) Mehaud (2019) M			
Lee (2017) Lee (2017) 1.14 (108, 1.31) 1.10 (0.78, 1.54) 1.26 (1.16, 1.60) 1.28 (1.31, 54) 1.28 (1.31,			
Mehadu (2018) 1.10 (7.3, 1.54) 13.58 Gown (2019) 1.28 (1.0.3, 1.54) 13.58 Overall (* 7.2.9%, p. = 0.001) 1.28 (1.0.3, 1.54) 100.0 Lung & bronchus 1.36 (1.16, 1.60) 12.31 Machaud (2006) 1.36 (1.16, 1.60) 12.31 Mai (2014) 1.26 (1.0.3, 1.54) 12.55 Chryannhacoulos (2016) 1.38 (1.14, 1.51) 12.32 Machaud (2017) 1.30 (1.14, 1.51) 12.32 Machaud (2017) 1.30 (1.14, 1.51) 12.36 Machaud (2019) 3.31 (1.14, 1.51) 12.36 Gewen(Males) (2019) 3.33 (1.0.8, 1.84) 4.38 Gewen(Males) (2019) 3.33 (1.0.8, 1.84) 4.38 Gewen(Males) (2019) 3.33 (1.0.8, 1.84) 4.38 Corenal (* e 63.7%, p. = 0.000) 1.33 (1.1.3, 1.50) 10.02 Colon & Cretum 1.56 (0.90, 1.23) 1.08 1.08 Mehaud (2016) 1.36 (1.1.3, 1.50) 10.67 1.38 Mehaud (2016) 1.56 (0.90, 1.23) 1.08 1.09 Mehaud (2016) 1.39 (0.7, 1.38 3.26 1.31 Mehaud (2016) 1.56			20.07
Given (2019) 18.4 (136, 2.49) 14.6 (136, 1.54) Coverall (# = 72.9%, p_0 = 0.001) 1.28 (10.3, 1.54) 100.0 Lung & bronchus 1.28 (10.3, 1.54) 100.0 Mechaud (2016) 1.28 (10.3, 1.54) 100.0 Lung & bronchus 1.28 (10.3, 1.54) 100.0 Mechaud (2016) 1.28 (10.3, 1.54) 12.33 Mechaud (2016) 1.28 (10.3, 1.54) 12.32 Chyannahokopoulos (2017) 1.38 (1.14, 1.51) 12.28 Mechaud (2016) 0.28 (0.43, 1.71) 3.44 Glowen (Meil (2017) 1.38 (1.14, 1.51) 12.80 Mechaud (2018) 2.37 (1.41, 3.99) 4.30 Glowen (Meil (2019) 2.51 (1.44, 4.33) 4.81 Colon & rectum 1.38 (1.64, 1.14) 1.15 Mechaud (2016) 1.39 (1.32, 1.39) 10.87 Mechaud (2016) 1.39 (1.43, 1.39) 10.87 Mechaud (2016) 1.39 (1.63, 1.35) 10.87 Mechaud (2016) 1.39 (1.64, 1.14) 1.15 Mechaud (2016) 1.39 (1.64, 1.14) 1.16 Mechaud (2016) 1.39 (1.64, 1.13) 1.39 (1.74, 1.39) Mec			13.58
Overall (P = 72.9%, p_0 = 0.001) 1.28 (1.03, 1.54) 100.0 Lung & bronchus 1.36 (1.16, 1.60) 12.31 Michaud (2008) 1.36 (1.16, 1.60) 12.31 Wan (2014) 1.96 (0.92, 1.27) 12.32 Chyaanthakopuolis (2016) 4.61 (0.55, 38.70) 0.43 Dickir (2017) 1.33 (1.14, 1.51) 12.86 Nichaud (2016) 0.59 (0.42, 1.74) 1.34 Ociveril (Male) (2019) 2.37 (14.13, 3.99) 4.36 Gönen(Male) (2019) 1.14 (0.62, 2.10) 3.22 Lu (2019) 2.57 (14.4, 3.33) 4.58 Yoon (2019) 1.33 (1.06, 1.64) 11.01 Voreall (P = 63.7%, p_o = 0.000) 1.35 (1.3, 1.59) 10.87 Wichaud (2016) 1.05 (0.90, 1.23) 10.87 Michaud (2016) 1.05 (0.90, 1.23) 10.87 Voreal (P = 63.7%, p_o = 0.000) 1.05 (0.90, 1.23) 10.87 Voreal (P = 63.7%, p_o = 0.000) 1.05 (0.90, 1.23) 10.87 Victor(2017) Nixia (2016) 1.05 (0.90, 1.23) 10.87 Michaud (2018) 1.05 (0.90, 1.23) <t< td=""><td></td><td></td><td>14.67</td></t<>			14.67
Mchaud (2006) 1.36 (1.16, 1.60) 12.3 (1.16, 1.60) 12.3 (1.16, 1.60) 12.3 (1.16, 1.60) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 10.5 (100.00
Mchaud (2006) 1.36 (1.16, 1.60) 12.3 (1.16, 1.60) 12.3 (1.16, 1.60) 12.3 (1.16, 1.60) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.05, 1.48) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 12.5 (1.02, 1.23) 10.5 (ung & bronchus		
Mail (2014) 1.28 (10.6, 1.48) 12.13 Chryanntakopoulos (2016) 1.68 (0.29, 127) 12.33 Mail (2016) 0.82 (0.48, 1.71) 3.44 Dizdar (2017) 1.70 (0.52, 4.64) 1.74 Han (2017) 1.33 (1.14, 1.51) 12.36 Oxiven(Male) (2019) 2.37 (1.14, 1.51) 12.36 Güwen(Male) (2019) 1.14 (0.62, 2.10) 3.22 Lu (2019) 1.26 (0.40, 0.69) 6.86 Yoon (2019) 1.30 (1.13, 1.50) 10.06 Overall (P = 6.3.7%, p.g = 0.000) 1.33 (1.13, 1.50) 10.07 Michaud (2016) 1.96 (0.56, 1.63) 4.31 Michaud (2016) 1.96 (0.56, 1.63) 4.31 Michaud (2016) 1.96 (0.56, 1.63) 4.31 Michaud (2017) 1.98 (0.56, 1.63) 4.31 Michaud (2018) 1.22 (1.1, 1.33) 6.67 Michaud (2018) 1.26 (1.1, 1.33)		4 26 /4 46 4 60	40.04
Wen (2014) 1.88 (0.02, 1.27) 12.32 Mai (2016) 1.59 (1.02, 2.31) 7.22 Mai (2016) 0.46 (0.05, 38.70) 0.43 Dizdar (2017) 1.87 (1.06, 2.31) 1.38 Han (2017) 0.55 (0.47, 1.27) 1.34 Nwitz (2017) 1.31 (1.14, 1.51) 1.28 Güwen(Fernale) (2019) 2.37 (1.14, 1.39) 4.59 Li (2018) 0.56 (0.40, 0.89) 6.88 Güwen(Fernale) (2019) 1.33 (1.13, 1.39) 0.26 Li (2019) 1.33 (1.13, 1.39) 1.30 (1.03, 3.35) 4.38 Yoon (2019) 1.33 (1.13, 1.39) 1.30 (1.03, 3.35) 4.38 Von (2019) 1.33 (1.13, 1.39) 1.02 1.33 (1.13, 1.39) 1.02 Colon & rectum 1.36 (0.06, 1.23) 1.08 0.87 1.38 (1.03, 1.38) 0.87 Michaud (2006) 1.32 (1.02, 1.33) 1.02 1.39 (1.03, 1.38) 0.87 Michaud (2016) 1.36 (0.66, 1.63) 4.31 1.35 (1.03, 0.57 1.38 (1.03, 1.58) 0.00 Von (2017) 0.58 (0.62, 1.17) 1.04 (0.33, 0.56, 1.63) 4.31 1.35 (0.69, 1.12) 1.25 (0.17, 1.34)			
chryanntakopoulos (2016) 1.58 (1.08, 2.31) 7.22 Michaud (2016) 4.61 (0.55, 38.7) 0.43 Dizdar (2017) 1.70 (0.82, 4.64) 1.74 Han (2017) 1.56 (0.71, 7.55) 1.34 Nethaud (2018) 2.37 (1.41, 3.99) 4.90 Güven(Male) (2019) 2.37 (1.41, 3.99) 4.90 Güven(Male) (2019) 1.14 (1082, 2.10) 3.92 Lu (2019) 1.33 (1.08, 1.64) 11.14 Tai (2019) 1.33 (1.08, 1.64) 11.14 Yoon (2019) 1.33 (1.08, 1.64) 11.15 Voor (2019) 1.33 (1.08, 1.64) 11.15 Voor (2016) 1.05 (0.60, 1.23) 10.87 Michaud (2016) 1.05 (0.60, 1.23) 10.87 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.96 (0.65, 1.63) 4.91 Nwizu (2017) 0.96 (0.65, 1.63) 4.91 Michaud (2016) 1.02 (0.77, 1.80) 3.67 Michaud (2016) 1.26 (1.17, 1.33) 3.67 Michaud (2017) 0.96 (0.65, 1.63) 4.91 Michaud (2016) 1.26 (1.77, 1.33) 3.68 <td></td> <td></td> <td></td>			
Mai (2016) Meihaud (2017) Michaud (2017) Han (2017) Michaud (2018) Güven(Meine (2019) Güven(Meine (2019) Li (2019) Colon & rectum Michaud (2006) Arcra (2010) Michaud (2016) Colon & rectum Michaud (2016) Michaud (2016) Colon & rectum Michaud (2016) Michaud (2016) Colon & rectum Michaud (2016) Michaud (2016) Colon & rectum Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2017) Colon & rectum Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2017) Colon & rectum Michaud (2016) Michaud (2017) Michaud (2016) Michaud (2017) Michaud (2016) Michaud (2016) Michaud (2017) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2017) Micha			
Mchaud (2016) 0.82 (0.48, 1.71) 3.84 Dickar (2017) 1.70 (0.82, 4.64) 1.74 Han (2017) 1.31 (1.41, 1.51) 1.28 Mchaud (2018) 2.37 (1.41, 3.59) 4.80 Göwen(Maie) (2019) 1.14 (0.82, 2.10) 3.82 Lu (2019) 1.14 (0.82, 2.10) 3.82 Lu (2019) 1.90 (1.08, 3.35) 4.80 Yoon (2019) 1.33 (1.08, 1.64) 11.15 Voor (2019) 1.33 (1.08, 1.64) 11.16 Voor (2010) 1.33 (1.08, 1.64) 11.15 Michaud (2016) 1.05 (0.90, 1.23) 10.87 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Michaud (2017) 0.96 (0.78, 1.16) 10.00 Nwizz (2017) 0.96 (0.78, 1.16) 10.00 Michaud (2018) 1.22 (0.51, 1.63) 4.91 Giwen(Meie (2019) 0.97 (0.37, 1.36) 3.26 Lu (2019) 1.77 (1.03, 3.05) 4.91			
Dizdar (2017) 1.70 (0.62, 4.64) 1.74 Han (2017) 0.55 (0.17, 1.75) 1.34 Nwizu (2017) 1.31 (1.14, 1.51) 12.80 Güven(Male) (2019) 0.60 (0.40, 0.89) 6.86 Güven(Female) (2019) 0.60 (0.40, 0.89) 6.86 Güven(Female) (2019) 2.51 (1.46, 4.33) 4.81 Tai (2019) 2.51 (1.46, 4.33) 4.81 Yoon (2019) 1.33 (1.08, 1.64) 11.11 Overall (P = 63.7%, p ₀ = 0.000) 1.33 (1.13, 1.50) 100.00 Colon & rectum 1.56 (0.90, 1.23) 10.87 Mehaud (2005) 1.05 (0.90, 1.23) 10.87 Arora (2010) 1.66 (1.43, 3.45) 0.63 Mehaud (2015) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.98 (0.82, 1.17) 10.48 Nwizu (2017) 0.98 (0.82, 1.13) 10.48 Chau (2016) 1.25 (1.71, 1.34) 12.20 Han (2017) 0.98 (0.82, 1.17) 10.48 Chau (2016) 1.26 (1.17, 1.34) 12.30 Han (2017) 0.98 (0.81, 1.62) 4.77 Overall (P= 79.0%, p ₀ = 0.000) 1.71 (1.33, 3.05)			
Han (2017) 0.55 (0.17, 1.75) 1.34 Michaud (2018) 2.37 (1.41, 3.99) 4.90 Güven(Finale (2019) 1.14 (0.62, 2.10) 3.82 Lu (2019) 1.30 (1.8, 1.64) 11.16 Tai (2016) 1.30 (1.3, 1.50) 10.00 Orverall (IF = 63.7%, p ₀ = 0.000) 1.05 (0.90, 1.23) 10.87 Arora (2016) 1.05 (0.90, 1.23) 10.87 Michaud (2006) 1.05 (0.90, 1.23) 10.87 Arora (2010) 1.05 (0.90, 1.23) 10.87 Michaud (2016) 1.05 (0.90, 1.23) 10.87 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.98 (0.82, 1.17) 10.48 Michaud (2016) 1.64 (1.48, 1.80) 12.03 Hu (2018) 1.64 (1.48, 1.80) 12.03 Lu (2017) 0.98 (0.82, 1.17) 10.40 Michaud (2016) 1.64 (1.48, 1.80) 12.03 Michaud (2018) 1.64 (1.48, 1.80) 12.03 Cibuen (Finale (2019) 1.14 (1.07, 1.22) 1.25 Güven (Finale (2019) 1.14 (1.07, 1.22) 1.25 Michaud (2016) 1.14 (1.07, 1.22)			
Nwizu (2017) 1.31 (1.14, 1.51) 12.80 Michaud (2015) 2.37 (1.41, 3.99) 4.80 Güven(Male) (2019) 0.60 (0.40, 0.89) 6.86 Güven(Fermale) (2019) 1.14 (1062, 2.10) 3.92 Lu (2019) 2.51 (1.46, 4.33) 4.81 Yoon (2019) 1.33 (1.08, 1.64) 11.14 Overall (P = 63.7%, p ₀ = 0.000) 1.33 (1.13, 1.50) 100.0 Colon & rectum 1.35 (0.91, 1.64) 11.44 (0.33, 1.50) 100.0 Mchaud (2005) 1.05 (0.90, 1.23) 10.87 Arror (2010) 1.62 (1.13, 2.33) 6.87 Michaud (2016) 1.04 (0.36, 1.03.9) 0.83 4.84 4.86 4.84 4.84			
Michaud (2018) 2.37 (1.41, 3.99) 4.90 Güven(Mie) (2019) 0.60 (0.40, 0.89) 6.86 Güven(Female) (2019) 2.51 (1.46, 4.33) 4.61 Tai (2019) 2.51 (1.46, 4.33) 4.61 Yoon (2019) 1.33 (1.08, 1.64) 11.14 Voor (2019) 1.33 (1.08, 1.64) 11.14 Overall (I ^P = 6.3.7%, p _o = 0.000) 1.05 (0.90, 1.23) 10.87 Michaud (2016) 1.05 (0.90, 1.23) 10.87 Michaud (2016) 1.06 (0.66, 1.39) 0.83 Michaud (2016) 1.08 (0.76, 1.39) 0.83 Michaud (2016) 1.09 (0.86, 1.39) 0.83 Michaud (2016) 1.09 (0.86, 1.39) 0.83 Michaud (2016) 1.08 (0.76, 1.39) 0.83 Michaud (2016) 1.22 (0.91, 1.63) 0.80 Michaud (2018) 1.22 (0.91, 1.63) 1.09 Lu (2017) 0.96 (0.56, 1.63) 1.51 (0.50, 2.52) Michaud (2018) 1.51 (0.50, 2.52) 4.54 Güven(Female) (2019) 1.51 (0.50, 2.52) 4.54 Güven(Female) (2019) 1.77 (1.33, 3.65) 4.190 Civen(Female) (2019)			
Given(Rvale) (2019) 0.60 (0.40, 0.89) 6.86 Given(Female) (2019) 1.14 (0.62, 2.10) 3.82 La (2019) 1.90 (1.08, 3.35) 4.86 Yoon (2019) 1.90 (1.08, 3.35) 4.81 Overall (P = 63.7%, po = 0.000) 1.90 (1.08, 3.35) 4.86 Michaud (2006) 1.95 (0.90, 1.23) 10.87 Acrora (2010) 1.95 (0.90, 1.23) 10.87 Michaud (2016) 1.95 (0.90, 1.23) 10.87 Michaud (2016) 1.96 (0.86, 1.63) 4.31 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Nwizu (2017) 1.22 (0.91, 1.63) 8.07 Nwizu (2017) 0.98 (0.86, 1.63) 4.31 Given(Maie) (2019) 1.25 (1.71, 1.34) 12.23 Lu (2018) 1.51 (0.90, 2.52) 4.54 Given(Maie) (2019) 1.51 (1.62) 4.77 Given(Maie) (2019) 1.51 (1.62) 4.77 Given(Maie) (2019) 0.77 (1.03, 1.36) 3.26 Lu (2019) 0.77 (1.03, 1.36) 3.26 Verall (P = 78.0%, po = 0.000) 1.76 (1.07, 1.28) 3.25 Michaud (2016) 1.14 (1.07, 1.22)<			
$\begin{array}{c} \text{Given(Female) (2019)} \\ \text{Lu (2019)} \\ \text{Tai (2019)} \\ \text{Coloral (} (l^2 = 63.7\%, p_0 = 0.000) \\ \hline \\ \text{Coloral } (l^2 = 63.7\%, p_0 = 0.000) \\ \hline \\ \text{Coloral } (l^2 = 63.7\%, p_0 = 0.000) \\ \hline \\ \text{Michaud (2008)} \\ \text{Acora (2010)} \\ \text{Michaud (2016)} \\ \text{Michaud (2016)} \\ \text{Han (2017)} \\ \text{Coloral } (l^2 = 79.0\%, p_0 = 0.000) \\ \hline \\ \text{Total cancer} \\ \hline \\ \text{Michaud (2018)} \\ \text{Civerall (} (l^2 = 9.000) \\ \hline \\ \text{Coloral } (l^2 = 9.000) \\ \hline \\ \text{Michaud (2018)} \\ \text{Coloral } (l^2 = 79.0\%, p_0 = 0.000) \\ \hline \\ \hline \\ \text{Coloral } (l^2 = 79.0\%, p_0 = 0.000) \\ \hline \\ \hline \\ \text{Coloral } (l^2 = 79.0\%, p_0 = 0.000) \\ \hline \\ \hline \\ \text{Coloral } (l^2 = 79.0\%, p_0 = 0.000) \\ \hline \\ \hline \\ \text{Coloral } (l^2 = 79.0\%, p_0 = 0.000) \\ \hline \\ \hline \\ \hline \\ \text{Coloral } (l^2 = 79.0\%, p_0 = 0.000) \\ \hline \\ \hline \\ \hline \\ \hline \\ \text{Coloral } (l^2 = 79.0\%, p_0 = 0.000) \\ \hline \\ $			
Lu (2019) Tai (2019) Tai (2019) (2019) Correctum Michaud (2008) Arora (2010) Michaud (2016) Han (2017) Han (2017) Han (2017) Chou (2018) Lee (2018) Michaud (2016) Lee (2018) Michaud (2016) Lee (2018) Michaud (2016) Lee (2018) Michaud (2016) Lee (2018) Michaud (2016) Lee (2018) Michaud (2016) Lee (2019) Coverall ($f^2 = 79.0\%$, $p_0 = 0.000$) Total cancer Michaud (2016) Michaud (2018) Güven(female) (2019) Liz (0.17, 1.88) Liz (0.18) Civer (female) (2019) Liz (0.144) Liz (0.16, 1.48) Liz (0.16, 1.48) Liz (0.17, 1.48) Liz (0.18) Civer (female) (2019) Liz (0.18) Liz (0.18) Liz (0.18) Liz (0.18) Liz (0.18) Liz (0.18) Liz (0.18)			
Tai (2019) 1.90 (1.08, 3.35) 4.36 Yoon (2019) 1.33 (1.08, 1.64) 11.15 Overall (i ² = 93.7%, p. 0.000) 1.30 (1.13, 1.50) 100.07 Michaud (2008) 1.05 (0.90, 1.23) 10.87 Arora (2010) 1.62 (1.13, 1.30) 0.87 Michaud (2016) 1.94 (0.36, 10.33) 0.63 Michaud (2016) 1.94 (0.36, 10.33) 0.63 Michaud (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.98 (0.82, 1.17) 10.48 Chou (2018) 1.26 (1.17, 1.34) 12.23 Michaud (2018) 1.56 (0.90, 2.52) 4.54 Güven(Male) (2019) 0.99 (0.61, 1.62) 4.77 Lu (2018) 1.26 (1.17, 1.34) 12.33 Lu (2018) 1.51 (1.09, 2.52) 4.54 Güven(Male) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 1.71 (1.03, 3.05) 4.19 Overall (i ² = 79.0%, p. = 0.000) 1.18 (1.01, 1.27) 12.51 Michaud (2008) 1.14 (1.07, 1.22) 12.51 Arise (2016) 1.20 (0			
Yoon (2019) 1.33 (1.08, 1.64) 11.15 Overall ($P = 63.7\%$, $p_0 = 0.000$) 1.30 (1.13, 1.50) 100.0 Colon & rectum 1.05 (0.90, 1.23) 10.87 Michaud (2008) 1.05 (0.90, 1.23) 10.87 Arora (2016) 1.62 (1.13, 2.33) 6.67 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.98 (0.82, 1.17) 0.98 (0.82, 1.17) Niktaud (2018) 0.95 (0.78, 1.16) 10.00 Lee (2018) 1.51 (0.90, 2.52) 4.54 Güven(Kmale) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.71 (0.33, 0.55) 4.19 Overall ($P = 79.0\%$, $p_0 = 0.000$) 1.18 (1.03, 1.36) 10.00 Verall ($P = 79.0\%$, $p_0 = 0.000$) 1.14 (107, 1.22) 1.25 (1.71, 1.34) Verall ($P = 79.0\%$, $p_0 = 0.000$) 1.18 (1.03, 1.36) 1.00 Verall ($P = 79.0\%$, $p_0 = 0.000$) 1.14 (107, 1.22) 1.25 (1.11, 1.36) Michaud (2008) 1.14 (107, 1.22) 1.25 (1.20, 1.132) 1.25 (1.20, 1.132) Michaud (2016) 1.13 (1.01, 1.27) 5.26 1.15 (0.			
Overail ($P = 63.7\%, p_0 = 0.000$) 1.30 (1.13, 1.50) 100.0 Michaud (2008) 1.05 (0.90, 1.23) 10.87 Michaud (2016) 1.62 (1.13, 2.33) 6.67 Michaud (2016) 1.04 (0.38, 10.35) 0.63 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.96 (0.56, 1.63) 4.31 Nixizu (2017) 0.98 (0.82, 1.17) 10.48 Chou (2018) 1.51 (0.90, 2.52) 4.54 Civen(Male (2018) 1.51 (0.90, 2.52) 4.54 Güven(Female) (2019) 0.99 (0.61, 1.62) 4.77 Güven(Kiel (2019) 0.99 (0.61, 1.62) 4.77 Güven(Kiel (2019) 0.99 (0.61, 1.62) 4.77 Güven(Kiel (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 1.18 (1.03, 1.36) 10.00 Cverall ($P = 79.0\%, p_0 = 0.000$) 1.18 (1.03, 1.36) 10.00 Verall ($P = 79.0\%, p_0 = 0.000$) 1.18 (1.01, 1.27) 1.52 Verall ($P = 79.0\%, p_0 = 0.000$) 1.18 (1.01, 1.27) 1.52 Verall ($P = 79.0\%, p_0 = 0.000$) 1.18 (1.01, 1.27) 1.			
Michaud (2008) 1.05 (0.90, 1.23) 10.87 Arora (2010) 1.62 (1.13, 2.33) 6.67 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.98 (0.82, 1.17) 10.48 Nwizu (2017) 0.98 (0.82, 1.17) 10.48 Chou (2018) 0.95 (0.78, 1.16) 10.000 Lee (2018) 1.51 (0.90, 2.52) 4.54 Güven(Kmale) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.71 (0.33, 0.55) 4.19 Overall (P = 79.0%, p.g = 0.000) 1.18 (1.03, 1.36) 10.00 Ver (2014) 1.15 (0.09, 1.11) 13.54 Chung (2016) 1.13 (1.01, 1.27) 8.59 Michaud (2016) 1.23 (1.19, 1.27) 1.52 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.33 (1.01, 1.27) 8.59 Dizdar (2017) 1.44 (1.02, 1.25) 1.58			100.00
Michaud (2008) 1.05 (0.90, 1.23) 10.87 Arora (2010) 1.62 (1.13, 2.33) 66.7 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.26 (0.56, 1.63) 4.31 Nwizu (2017) 0.28 (0.82, 1.17) 10.48 Chou (2018) 0.95 (0.78, 1.16) 10.000 Hu (2018) 1.51 (0.90, 2.52) 4.54 Güven(Kmale) (2019) 0.99 (0.61, 1.62) 4.77 Güven(Kmale) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2018) 1.14 (1.07, 1.22) 1.25 (1.17, 1.34) 12.30 Veraul (2 ² = 79.0%, p ₀ = 0.000) 1.77 (1.03, 3.05) 4.19 Overaul (2 ² = 79.0%, p ₀ = 0.000) 1.14 (1.07, 1.22) 1.25 (1.17, 1.34) Veraul (2 ² = 79.0%, p ₀ = 0.000) 1.77 (1.33, 0.5) 4.19 Overaul (2 ² = 79.0%, p ₀ = 0.000) 1.14 (1.07, 1.22) 1.25 (1.17, 1.34) Michaud (2008) 1.14 (1.07, 1.22) 1.25 (1.17, 1.34) Arora (2016) 1.26 (0.77, 1.86) 1.20 Michaud (2016) 1.33 (1.01, 1.27) 5.59 Dizdar (2017)	Colon & restum		
Arora (2010) 182 (113, 2.33) 6.67 Mai (2016) 1.94 (0.36, 10.35) 0.63 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.96 (0.56, 1.63) 4.31 Nwizu (2017) 0.98 (0.82, 1.17) 10.48 Chou (2018) 0.95 (0.78, 1.16) 10.00 Lee (2018) 1.55 (1.17, 1.34) 12.20 Michaud (2018) 1.55 (1.17, 1.34) 12.30 Güven(Kenale) (2019) 0.79 (0.37, 1.36) 3.26 Lu (2018) 1.14 (1.07, 1.22) 1.25 (1.17, 1.34) Overall (# = 79.0%, p ₀ = 0.000) 1.18 (10.3, 1.36) 10.00 Total cancer 1.14 (1.07, 1.22) 1.25 (1.17, 1.34) 1.35 (1.16) Michaud (2008) 1.14 (1.07, 1.22) 1.25 (1.17, 1.34) 1.35 (1.16) 10.00 Total cancer 1.14 (1.07, 1.22) 1.25 (1.17, 1.34) 1.35 (1.16) 1.00 Michaud (2016) 1.13 (1.01, 1.27) 1.52 (1.17, 1.36) 1.36 (1.16) 1.35 (1.16) 1.35 (1.16) 1.35 (1.16) 1.35 (1.16) 1.35 (1.16) 1.35 (1.16) 1.35 (1.16)		4.05 /0.00 4.00	10.07
Mai (2016) 1.94 (0.36, 10.35) 0.63 Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 0.98 (0.82, 1.17) 10.48 Chou (2018) 0.95 (0.78, 1.16) 10.00 Hu (2018) 1.25 (1.17, 1.34) 12.23 Göwen(Male) (2019) 0.99 (0.61, 1.62) 4.77 Göwen(Male) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2018) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.71 (0.37, 1.36) 3.26 Chard (2008) 1.14 (1.07, 1.22) 1.25 f Aora (2010) 1.18 (1.03, 1.36) 1000 Ven (2014) 1.05 (0.99, 1.11) 13.54 Chung (2016) 1.13 (1.01, 1.27) 8.59 Dizdar (2017) 1.13 (1.01, 1.27) 8.59 Dizdar (2017) 1.32 (1.19, 1.27) 1.52 Michaud (2018) 1.06 (0.59, 1.19) 1.74 Michaud (2016) 1.13 (1.01, 1.27) 8.59 Dizdar (2017) 1.31 (1.01, 1.27) 8.59			
Michaud (2016) 1.03 (0.76, 1.39) 7.87 Han (2017) 0.96 (0.56, 1.63) 4.31 Momen-Heravi (2017) 1.22 (0.91, 1.63) 8.07 Nwizu (2017) 0.98 (0.82, 1.17) 10.48 Chou (2018) 0.95 (0.78, 1.16) 10.000 Hu (2018) 1.51 (0.90, 2.52) 4.54 Güven(Kmale) (2019) 0.99 (0.61, 1.62) 4.77 Güven(Kmale) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 1.18 (1.03, 1.36) 4.19 Overatil (# = 79.0%, p ₀ = 0.000) 1.77 (1.03, 3.05) 4.19 Overatil (# = 79.0%, p ₀ = 0.000) 1.78 (1.03, 1.36) 1.05 Ven (2016) 1.14 (1.07, 1.22) 12.51 Michaud (2008) 1.14 (1.07, 1.22) 12.51 Arora (2016) 1.13 (1.01, 1.27) 8.59 Dizdar (2017) 1.26 (0.77, 1.86) 1.20 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Dizdar (2017) 1.25 1.58			
Han (2017) Momen-Heravi (2017) Nixizu (2017) Chu (2018) Lee (2018) Lee (2018) Lee (2018) Lee (2018) Lee (2018) Lee (2018) Chu (2019) Coverall (f = 79.0%, p_o = 0.000) Total cancer Michaud (2016) Michaud (2016) Total (2017) Michaud (2016) Michaud (2018) Güven(Male) (2019) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2018) Güven(Male) (2019) Michaud (2016) Michaud (2018) Michaud (2018) Güven(Male) (2019) Michaud (2019) Michaud (2016) Michaud (2018) Güven(Male) (2019) Michaud (2019) Michaud (2018) Güven(Male) (2019) Michaud (2019) Michaud (2018) Güven(Male) (2019) Michaud (2019) Michaud (2019) Michaud (2018) Güven(Male) (2019) Michaud (2019) Michaud (2019) Michaud (2018) Güven(Male) (2019) Michaud (2018) Michaud			
Momen-Heravi (2017) 1.22 (0.91, 1.63) 9.07 Nwizu (2017) 0.98 (0.82, 1.17) 10.48 Chou (2018) 0.95 (0.78, 1.16) 10.00 Hu (2018) 1.45 (1.49, 1.80) 12.03 Lee (2018) 1.51 (0.90, 2.52) 4.54 Güven(Male) (2019) 0.97 (0.61, 1.62) 4.57 Lu (2019) 0.97 (0.61, 1.62) 4.54 Güven(Female) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.77 (1.03, 3.05) 4.19 Overall (P = 79.0%, po = 0.000) 1.18 (1.03, 1.36) 1000 Vera (2014) 1.14 (1.07, 1.22) 1.251 Arcra (2010) 1.14 (1.07, 1.22) 1.251 Michaud (2008) 1.14 (1.07, 1.22) 1.251 Arcra (2010) 1.15 (0.09, 1.21) 1.52 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.32 (1.19, 1.27) 1.52 Dizdar (2017) 1.73 (1.12, 1.258) 1.58 Michaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Female) (2019) 1.14 (1.08, 1.28) 6.98 Güven(Female) (2019) 1.14 (1.08, 1.48)			
Nwizu (2017) 0.98 (0.82, 1.17) 10.48 Chou (2018) 0.95 (0.78, 1.16) 10.00 Hu (2018) 1.64 (1.49, 1.80) 12.03 Lee (2018) 1.55 (1.71, 1.34) 12.33 Güven(Male) (2019) 0.99 (0.61, 1.62) 4.77 Güven(Female) (2019) 0.77 (1.03, 3.05) 4.19 Overall (² = 79.0%, po = 0.000) 1.18 (1.03, 1.36) 10.00 Chichaud (2008) 1.14 (1.07, 1.22) 12.51 Arora (2016) 1.14 (1.07, 1.22) 12.51 Michaud (2008) 1.14 (1.07, 1.22) 12.51 Arora (2016) 1.13 (1.01, 1.32) 7.25 Michaud (2016) 1.23 (1.19, 1.27) 15.26 Mai (2016) 1.23 (1.19, 1.27) 15.26 Mai (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Dizdar (2017) 1.77 (1.21, 2.58) 1.58 Güven(Male) (2018) 1.06 (0.90, 1.25) 5.85 Güven(Male) (2018) 1.06 (0.90, 1.25) 5.85 Güven(Male) (2019) 1.14 (1.08, 1.48) 6.98 Güven(Male) (2019) 1.24 (1.06, 1.45) </td <td></td> <td></td> <td></td>			
Chou (2018) 0.95 (0.78, 1.16) 10.00 Hu (2018) 1.64 (1.49, 1.80) 12.03 Lee (2018) 1.55 (1.30, 2.52) 4.54 Güwen(Mele (2019) 0.99 (0.61, 1.62) 4.77 Güwen(Mele (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.71 (0.37, 1.36) 3.26 Cure (Xiel) 1.18 (1.03, 1.36) 100 Vorrall (² = 79.0%, p _Q = 0.000) 1.18 (1.03, 1.36) 100 Fotal cancer Michaud (2008) 1.14 (1.07, 1.22) 1.25 Arora (2010) 1.15 (1.00, 1.32) 7.25 Wen (2014) 1.05 (0.99, 1.11) 13.54 Chung (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Dizdar (2017) 1.74 (1.22, 1.58) 1.58 Michaud (2016) 1.77 (1.21, 2.58) 1.58 Güwen(Male) (2018) 1.06 (0.90, 1.25) 5.85 Güwen(Male) (2018) 1.14 (1.08, 1.48) 6.98 Güwen (Male) (2019) 1.14 (1.06, 1.48) 6.98 Güwen (Male) (2019) 1.14 (1.06, 1.46) 6.36 L			
Hu (2018) 1.64 (1.49, 1.60) 12.03 Lee (2018) 1.25 (1.17, 1.34) 12.33 Michaud (2018) 1.51 (0.90, 2.52) 4.54 Güven(Male) (2019) 0.99 (0.61, 1.62) 4.77 Güven(Female) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 1.77 (1.03, 3.05) 4.19 Overall (2* 79.0%, p ₀ = 0.000) 1.78 (1.03, 1.36) 10.00 Verall (2* 79.0%, p ₀ = 0.000) 1.18 (1.00, 1.32) 7.251 Kichaud (2008) 1.14 (1.07, 1.22) 12.51 Arora (2010) 1.15 (1.00, 1.32) 7.255 Wen (2014) 1.05 (0.99, 1.11) 13.54 Chung (2016) 1.23 (1.19, 1.27) 15.20 Michaud (2016) 1.20 (0.77, 1.46) 1.20 Michaud (2016) 1.33 (1.01, 1.27) 8.59 Dizdar (2017) 1.73 (1.21, 2.58) 1.58 Han (2017) 0.84 (0.58, 1.19) 1.74 Nvizu (2017) 1.14 (1.08, 1.20) 1.38 Michaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Male) (2019) 1.11 (0.96, 1.28)			
Lee (2018) Michaud (2018) Given(Male) (2019) Given(Male) (2019) Given(Male) (2019) Lu (2019) Coverall (l ² = 79.0%, p _o = 0.000) Coverall (l ² = 1.00, l ² = 1.00, l ² = 1.00, l ² = 1.00, l ² = 1.00,			
Michaud (2018) 1.51 (0.90, 2.52) 4.54 Güven(Female) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 1.77 (1.03, 3.05) 4.19 Overall (? = 79.0%, p _o = 0.000) 1.18 (1.03, 1.36) 1000 Fotal cancer Michaud (2008) 1.14 (1.07, 1.22) 1.251 Arora (2010) 1.15 (0.09, 1.32) 7.25 Ven(2014) 1.05 (0.99, 1.11) 13.54 Chung (2016) 1.23 (1.19, 1.27) 15.26 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.33 (1.01, 1.27) 8.59 Dizdar (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 0.84 (0.58, 1.19) 1.74 Nichaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Female) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Female) (2019) 1.24 (1.06, 1.46) 6.26 Lu (2019) 1.24 (1.06, 1.40) 5.36			
Güven(Male) (2019) 0.99 (0.61, 1.62) 4.77 Güven(Female) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 1.77 (1.03, 3.05) 4.19 Overall (l ² = 79.0%, p ₀ = 0.000) 1.18 (1.03, 1.36) 100.0 Contail cancer Michaud (2008) 1.14 (1.07, 1.22) 12.51 Arora (2010) 1.15 (1.00, 1.32) 7.25 Mai (2016) 1.23 (1.19, 1.27) 15.26 Mai (2016) 1.23 (1.19, 1.27) 15.26 Mai (2016) 1.31 (1.01, 1.27) 8.59 Dizdar (2017) 1.77 (1.21, 2.58) 1.58 Michaud (2018) 1.06 (0.59, 1.19) 1.74 Michaud (2018) 1.06 (0.99, 1.25) 5.85 Güven(Male) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Female) (2019) 1.14 (1.08, 1.45) 6.25 Lu (2019) 1.14 (1.08, 1.45) 6.28 Güven(Male) (2019) 1.14 (1.08, 1.45) 6.98 Güven(Male) (2019) 1.24 (1.06, 1.45) 6.98 Güven(Male) (2019) 1.20 (0.91, 1.30) 5.36			
Güven(Remale) (2019) 0.71 (0.37, 1.36) 3.26 Lu (2019) 1.77 (1.03, 3.05) 4.19 Overall (° = 79.0%, p _o = 0.000) 1.18 (1.03, 1.36) 100.0 Fotal cancer 1.14 (1.07, 1.22) 12.51 Michaud (2008) 1.14 (1.07, 1.22) 12.51 Arora (2010) 1.15 (1.00, 1.32) 7.25 Wen (2014) 1.05 (0.99, 1.11) 13.54 Chung (2016) 1.23 (1.19, 1.27) 15.26 Michaud (2016) 1.23 (1.19, 1.27) 15.26 Dizdar (2017) 1.13 (1.01, 1.27) 8.59 Han (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 1.14 (1.08, 1.20) 13.88 Michaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Male) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Fermale) (219) 1.14 (1.08, 1.40) 5.36			
Lu (2019) Overall (l ² = 79.0%, p _o = 0.000) Total cancer Michaud (2008) Arora (2010) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2016) Michaud (2017) Michaud (2018) Michaud (2018) Michaud (2018) Michaud (2018) Michaud (2018) Michaud (2018) Michaud (2018) Güven(Male) (2019) Li de (10, 122) Michaud (2018) Güven(Male) (2019) Li de (10, 122) Li de (10, 122) Michaud (2018) Michaud (2018) Michaud (2018) Michaud (2019) Michaud (2019) Michau			
Overall (I ² = 79.0%, p ₀ = 0.000) 1.18 (1.03, 1.36) 100.0 Total cancer			
Michaud (2008) 1.14 (1.07, 1.22) 12.51 Arora (2010) 1.15 (1.00, 1.32) 7.25 Wein (2014) 1.05 (1.00, 1.32) 7.25 Chung (2016) 1.23 (1.19, 1.27) 15.26 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.77 (1.21, 2.58) 1.58 Dizdar (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 0.84 (0.58, 1.19) 1.74 Michaud (2018) 0.66 (0.90, 1.25) 5.85 Güven(Kale) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Female) (2019) 1.24 (1.06, 1.45) 6.29 Lu (2019) 1.09 (0.91, 1.30) 5.36			100.00
Michaud (2008) 1.14 (1.07, 1.22) 12.51 Arora (2010) 1.15 (1.00, 1.32) 7.25 Wen (2014) 1.05 (1.00, 1.32) 7.25 Chung (2016) 1.23 (1.19, 1.27) 15.26 Michaud (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.77 (1.21, 2.58) 1.58 Dizdar (2017) 1.77 (1.21, 2.58) 1.58 Michaud (2018) 0.66 (0.90, 1.25) 5.85 Güven(Male) (2019) 1.14 (1.08, 1.48) 6.98 Güven(Female) (2019) 1.24 (1.06, 1.45) 6.98 Lu (2017) 1.24 (1.06, 1.43) 6.98	Fotal cancer		
Arcra (2010) 1.15 (1.00, 1.32) 7.25 Wen (2014) 1.05 (0.99, 1.11) 13.54 Chung (2016) 1.20 (0.77, 1.86) 1.20 Mai (2016) 1.20 (0.77, 1.86) 1.20 Dizdar (2017) 1.13 (1.01, 1.27) 8.59 Han (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 0.84 (0.58, 1.19) 1.74 Michaud (2018) 0.06 (0.90, 1.25) 5.85 Güven(Kenele) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Female) (2019) 1.24 (1.06, 1.45) 6.25 Lu (2019) 5.36 5.36		1 14 /4 07 4 00	10 54
Wen (2014) 105 (0.99, 1.11) 13.54 Chung (2016) 1.23 (1.19, 1.27) 15.26 Mai (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.13 (1.01, 1.27) 8.59 Dizdar (2017) 177 (1.21, 2.58) 1.58 Han (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 1.14 (1.08, 1.20) 1.38 Güven(Male) (2018) 1.06 (0.90, 1.25) 5.85 Güven(Female) (2019) 1.11 (0.96, 1.28) 6.98 Lu (2019) 1.24 (1.06, 1.45) 6.37 Lu (2019) 5.36 1.09 (0.91, 1.30) 5.36			
Chung (2016) 1.23 (1.19, 1.27) 15.26 Mai (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.13 (1.01, 1.27) 8.59 Dizdar (2017) 1.77 (1.21, 2.58) 1.58 Han (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 1.14 (1.08, 1.20) 13.89 Michaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Female) (2019) 1.11 (0.96, 1.45) 6.98 Güven(Female) (2019) 1.20 (0.91, 1.30) 5.36			
Mai (2016) 1.20 (0.77, 1.86) 1.20 Michaud (2016) 1.31 (1.01, 1.27) 8.59 Dizdar (2017) 1.77 (1.21, 2.58) 1.58 Han (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 0.84 (0.58, 1.19) 1.74 Süven(Male) (2018) 1.06 (0.90, 1.25) 5.85 Güven(Female) (2019) 1.11 (0.96, 1.28) 6.98 Lu (2019) 1.24 (1.06, 1.45) 6.25 Lu (2019) 1.24 (1.06, 1.45) 6.38			
Mchaud (2016) 1.13 (1.01, 1.27) 8.59 Dizdar (2017) 1.77 (1.21, 2.58) 1.58 Han (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 1.14 (1.08, 1.20) 1.38 Kichaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Male) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Female) (2019) 1.24 (1.06, 1.45) 6.25 Lu (2019) 1.09 (0.91, 1.30) 5.36			
Dizdar (2017) 1.77 (1.21, 2.58) 1.58 Han (2017) 0.84 (0.58, 1.19) 1.74 Nvizu (2017) 1.14 (1.08, 1.20) 13.88 Michaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Male) (2019) 1.12 (1.06, 1.45) 6.28 Lu (2019) 1.24 (1.06, 1.45) 6.25 Lu (2019) 5.36 1.99 (0.91, 1.30) 5.36			
Han (2017) 0.84 (0.58, 1.19) 1.74 Nwizu (2017) 1.14 (1.08, 1.20) 13.89 Michaud (2018) 0.06 (0.90, 1.25) 5.85 Güven(Kemale) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Fermale) (2019) 1.24 (1.06, 1.45) 6.25 Lu (2019) 1.29 (0.91, 1.30) 5.36			
Nwizu (2017) 1.14 (1.08, 1.20) 1.38 Michaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Male) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Female) (2019) 1.24 (1.06, 1.45) 6.92 Lu (2019) 1.24 (1.06, 1.45) 5.36			
Michaud (2018) 1.06 (0.90, 1.25) 5.85 Güven(Male) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Fernale) (2019) 1.24 (1.06, 1.45) 6.25 Lu (2019) 1.09 (0.91, 1.30) 5.36			
Güven(Male) (2019) 1.11 (0.96, 1.28) 6.98 Güven(Female) (2019) 1.24 (1.06, 1.45) 6.25 Lu (2019) 0.90 (0.91, 1.30) 5.36			
Güven(Female) (2019) 1.24 (1.06, 1.45) 6.25 Lu (2019) 1.09 (0.91, 1.30) 5.36			
Lu (2019) 1.09 (0.91, 1.30) 5.36			
Overall (* = 67.4%, po = 0.000) 100.0			
	Overall (I* = 67.4%, p _Q = 0.000)	1.14 (1.08, 1.20)	100.00

Figure 2 Forest plots of the association between periodontitis and cancer incidence.

Full-size DOI: 10.7717/peerj.14320/fig-2

	HR	LCI	UCI		HR	(95%CI)	
Breast							
Arora (2010)	1.27	1.11	1.45			0	
Wen (2014)	1.30	1.13	1.49			0	
Chung (2016)	1.27	1.08	1.48	- I		0	
Freudenheim (2016)	1.29	1.11	1.50			0	
Mai (2016)	1.27	1.11	1.44		I	0	
Dizdar (2017)	1.24	1.09	1.40	- Free	0		
Han (2017)	1.25	1.09	1.42	E-	c		1
Nwizu (2017)	1.29	1.10	1.51	j.		0	
Sfreddo (2017)	1.23	1.08	1.40	- Freedow	0		
Michaud (2018)	1.28	1.12	1.46		1	0	
Güven (2019)	1.15	1.07	1.24	1	o I		
rostate				1.07 1.	11	1.26	1.43 1.51
	1.05	1 10	1.05		[T
Michaud (2008)	1.35	1.10	1.65			0	
Arora (2010)	1.23	0.99	1.53	I	0		
Michaud (2016)	1.30	1.01	1.66	1		0	
Dizdar (2017)	1.21	1.00	1.45	1	0	· · · · · · · · · · · · · · · · · · ·	
Lee (2017)	1.32	1.00	1.73	I-		0	1
Michaud (2018)	1.30	1.03	1.63			0	
Güven (2019)	1.16	0.97	1.38	I	0		
ung & bronchus					1.03	1.26	1.54 1.7
Michaud (2008)	1.30	1.10	1.53				
Mai (2014)	1.31	1.11	1.54			0	
Wen (2014)	1.33	1.14	1.56			0	
Chrysanthakopoulos (2016)	1.28	1.10	1.48	para la construcción de la const	0		
Mai (2016)	1.29	1.12	1.49		C		
Michaud (2016)	1.32	1.14	1.52	- F		0	
Dizdar (2017)	1.29	1.12	1.49	i i i i i i i i i i i i i i i i i i i			
Han (2017)	1.31	1.14	1.51			0	
Nwizu (2017)	1.30	1.10	1.54	1		0	
Michaud (2018)	1.26	1.10	1.44	1	0		
Güven (Male) (2019)	1.35	1.20	1.52		1		
Güven (Female) (2019)	1.31	1.13	1.51			0	
Lu (2019)	1.26	1.10	1.44	[0	·	
Tai (2019)	1.28	1.11	1.47				
Yoon (2019)	1.30	1.11	1.52				
olon & rectum				1.101.13	1	.30	1.50 1.56
Michaud (2008)	1.20	1.04	1.39	E.		0	1
Arora (2010)	1.16	1.00	1.33	1	0		
	1.18	1.03	1.35			3	
		1.04	1.38	les les		0	
Michaud (2016)	1.20			ľ			
Michaud (2016) Han (2017)	1.20	1.04	1.37	1-		0	
Michaud (2016) Han (2017) Momen-Heravi(2017)	1.20 1.18	1.04	1.37 1.36	l- I-		0	
Michaud (2016) Han (2017) Momen-Heravi(2017) Nwizu (2017)	1.20 1.18 1.21	1.04 1.02 1.05	1.37 1.36 1.39	l		000	
Michaud (2016) Han (2017) Momen-Heravi(2017) Mwizu (2017) Chou (2018)	1.20 1.18 1.21 1.21	1.04 1.02 1.05 1.06	1.37 1.36 1.39 1.40	j. Jeres		C	
Michaud (2016) Han (2017) Momen-Heravi(2017) Nwizu (2017) Chou (2018) Hu (2018)	1.20 1.18 1.21 1.21 1.12	1.04 1.02 1.05 1.06 1.02	1.37 1.36 1.39 1.40 1.25	F Ferrar Ferrar	······································	0	
Michaud (2016) Han (2017) Momen-Heravi(2017) Nwizu (2017) Chou (2018) Hu (2018) Lee (2018)	1.20 1.18 1.21 1.21 1.12 1.12	1.04 1.02 1.05 1.06 1.02 0.98	1.37 1.36 1.39 1.40 1.25 1.40	F		0	
Michaud (2016) Han (2017) Momen-Heravi(2017) Mwizu (2017) Chou (2018) Hu (2018) Lee (2018) Michaud (2018)	1.20 1.18 1.21 1.21 1.12 1.17 1.17	1.04 1.02 1.05 1.06 1.02 0.98 1.02	1.37 1.36 1.39 1.40 1.25 1.40 1.35			0	
Michaud (2016) Han (2017) Weizu (2017) Chou (2018) Hu (2018) Lee (2018) Michaud (2018) Süven(Male)(2019)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37			0	
Michaud (2016) Han (2017) Mwizu (2017) Nwizu (2017) Chou (2018) Hu (2018) Lee (2018) Michaud (2018) Given (Male) (2019) Given (Male) (2019)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.19 1.20	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38		0 	0	
Michaud (2016) Han (2017) Mwizu (2017) Nwizu (2017) Chou (2018) Hu (2018) Lee (2018) Michaud (2018) Given (Male) (2019) Given (Male) (2019)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37	Francisco de la constante Francisco Francisco Francisco	0 	0 0 1	
Michaud (2016) Han (2017) Nwizu (2017) Chou (2018) Hu (2018) Eae (2018) Given (Male) (2019) Given (Female) (2019) Lu (2019)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.19 1.20	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38		0 	0 0 1	
Michaud (2016) Han (2017) Mwizu (2017) Nwizu (2017) End (2018) Hu (2018) Ede (2018) Michaud (2018) Siven(Male)(2019) Siven(Female)(2019) Ed (2019) Otal cancer	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.19 1.20	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38	Francisco de la constante Francisco Francisco Francisco	0 	0 0 1	
Aichaud (2016) Han (2017) Wrizu (2017) Wrizu (2017) Chou (2018) Au (2018) Eae (2018) Aiven (Male) (2019) Aiven (Female) (2019) Aiven (Female) (2019) Au (2019) Datal cancer Aichaud (2008)	1.20 1.18 1.21 1.22 1.12 1.17 1.17 1.19 1.20 1.16	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34	Francisco de la constante Francisco Francisco Francisco	0 	0 0 1	
fichaud (2016) Han (2017) Waizu (2017) Waizu (2017) Thou (2018) Lee (2018) Lee (2018) Michaud (2018) Siven (Male) (2019) Siven (Female) (2019) Lu (2019) Dtal cancer Michaud (2008) Larora (2010)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.20 1.16	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34	0.98 1.0:	0 	0 0 1	
Michaud (2016) Han (2017) Han (2017) Wrizu (2017) Stream - Herzwi (2017) Wrizu (2017) End (2018) Hu (2018) Ease (2018) Silven (Male) (2019) Silven (Female) (2019) La (2019) otal cancer Michaud (2008) Arora (2014)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.20 1.16	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34	0.98 1.0:	0 	0 0 0 1 18	
Aichaud (2016) Han (2017) Wrizu (2017) Wrizu (2017) Chou (2018) Lia (2018) Lia (2018) Aiven (Ale) (2019) Aiven (Female) (2019) Aiven (Female) (2019) Lia (2019) Dotal cancer Aichaud (2008) Licoxa (2010) Nen (2014) Thung (2016)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.19 1.20 1.16 1.14 1.14 1.14 1.16 1.12	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.04 1.05 1.01	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34	0.98 1.0:	0 	0 0 0 1 18	
#ichaud (2016) Han (2017) Han (2017) Wrizu (2017) Wrizu (2017) Edichaud (2018) Hu (2018) Lee (2018) Silven (Male) (2019) Lu (2019) Lu (2019) Lu (2019) Lu (2019) Lu (2019) Lu (2010) Verora (2010) Wen (2014) Chung (2016) Kai (2016)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.19 1.20 1.16 1.14 1.14 1.14 1.16 1.12 1.14	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34 1.21 1.20 1.21 1.20	0.98 1.0:	0 	0 0 0 1 18	
Michaud (2016) Han (2017) Nwizu (2017) Chou (2018) Hu (2018) Eee (2018) Michaud (2018) Siven (Male) (2019) Siven (Female) (2019) Lu (2019) otal cancer Michaud (2008) Arora (2010) Men (2014) Chung (2016) Michaud (2016)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.19 1.20 1.16 1.14 1.14 1.16 1.12 1.14 1.14	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01 1.08 1.08 1.18 1.07 1.08 1.08	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34 1.21 1.20 1.21 1.17 1.20 1.20	0.98 1.0:	0 	0 0 0 1 18	
Michaud (2016) Han (2017) Waizu (2017) Waizu (2017) Chou (2018) Hu (2018) Lee (2018) Michaud (2018) Silven (Male) (2019) Silven (Female) (2019) Lu (2019) Hotal cancer Michaud (2008) Arora (2010) Wen (2014) Chung (2016) Mai (2016) Michaud (2016) Dizdar (2017)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.19 1.20 1.16 1.14 1.14 1.14 1.14 1.12 1.14 1.14 1.13	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01 1.08 1.08 1.08 1.08 1.08 1.08 1.08	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34 1.21 1.20 1.21 1.17 1.20 1.19	0.98 1.0:	0 	0 0 0 1 18	
#ichaud (2016) Han (2017) Han (2017) Wrizu (2017) Wrizu (2017) Ban (2018) Hu (2018) Hu (2018) Silven (Male) (2019) Silven (Male) (2019) Lu (2019) Silven (Female) (2019) Silven (Arora (2019) Lu (2019) Silven (Kancer Michaud (2008) Warora (2010) Wen (2014) Thung (2016) Mai (2016) Michaud (2016) Silven (2017) Jian (2017) Silven (2017)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.19 1.20 1.16 1.14 1.14 1.14 1.14 1.14 1.14 1.12 1.14 1.13 1.15	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01 1.08 1.08 1.08 1.18 1.07 1.08 1.08 1.08 1.08 1.08 1.08 1.09	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34 1.21 1.20 1.21 1.20 1.20 1.20 1.19 1.20	0.98 1.0:	0 	0 0 0 0 0 1 1 1 8 0 0 1 0 0 1 0 0 0 0 0	
Michaud (2016) Han (2017) Nwizu (2017) Chou (2018) Hu (2018) Hu (2018) Eee (2018) Michaud (2018) Siven (Male) (2019) Siven (Female) (2019) Lu (2019) otal cancer Michaud (2008) Arora (2010) Man (2016) Michaud (2016) Michaud (2016) Dizdar (2017) Han (2017)	1.20 1.18 1.21 1.21 1.12 1.17 1.19 1.20 1.16 1.14 1.14 1.14 1.14 1.12 1.14 1.13 1.15 1.14	1.04 1.02 1.05 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01 1.08 1.08 1.08 1.08 1.08 1.08 1.08	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34 1.21 1.20 1.21 1.17 1.20 1.20 1.20 1.20 1.21		0 	0 0 0 0 0 1 1 1 8 0 0 1 0 0 1 0 0 0 0 0	
Michaud (2016) Han (2017) Nwizu (2017) Chou (2018) Hu (2018) Lee (2018) Michaud (2018) Given (Male) (2019) Given (Female) (2019) Lu (2019) otal cancer Michaud (2008) Arora (2010) Wan (2014) Chung (2016) Michaud (2016) Dizdar (2017) Han (2017) Nwizu (2017)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.19 1.20 1.16 1.14 1.14 1.14 1.14 1.12 1.14 1.13 1.15 1.14 1.14	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01 1.08 1.08 1.08 1.08 1.08 1.08 1.08	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34 1.21 1.20 1.21 1.17 1.20 1.19 1.20 1.21 1.20		0 	0 0 1 1 18 0 0 1 18	
Michaud (2016) Han (2017) Nwizu (2017) Nwizu (2017) Chou (2018) Hu (2018) Eae (2018) Given(Male)(2019) Given(Male)(2019) Lu (2019) ofal cancer Michaud (2019) Chung (2014) Chung (2016) Mei (2016) Michaud (2016) Dizdar (2017) Han (2017) Nwizu (2017) Michaud (2018) Given(Male) (2019)	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.19 1.20 1.16 1.14 1.14 1.14 1.14 1.14 1.14 1.13 1.15 1.14 1.14 1.14	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01 1.08 1.08 1.08 1.08 1.08 1.08 1.08	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34 1.21 1.20 1.21 1.20 1.20 1.21 1.20 1.21 1.20 1.21 1.20		0 	0 0 1 1 18 0 0 1 18	
	1.20 1.18 1.21 1.21 1.12 1.17 1.17 1.17 1.19 1.20 1.16 1.14 1.14 1.14 1.14 1.12 1.14 1.13 1.15 1.14 1.14	1.04 1.02 1.05 1.06 1.02 0.98 1.02 1.04 1.05 1.01 1.08 1.08 1.08 1.08 1.08 1.08 1.08	1.37 1.36 1.39 1.40 1.25 1.40 1.35 1.37 1.38 1.34 1.21 1.20 1.21 1.17 1.20 1.19 1.20 1.21 1.20		0 1 3 1 0	0 0 1 1 18 0 0 1 18	

Figure 3 Sensitivity analyses of the association between periodontitis and cancer incidence. Full-size DOI: 10.7717/peerj.14320/fig-3

Subgroups	No. of studies		Meta-analysis			Heterogeneity		
		HR	95%CI	P-value	I ² (%)	P-value		
Breast Cancer								
Study population								
North America	4	1.12	1.05-1.19	0.001	0.0	0.694		
Asia	3	1.16	1.00-1.35	0.044	53.1	0.119		
Europe	3	1.76	1.06-2.91	0.029	75.8	0.016		
South America	1	1.55	1.14-2.11	0.006	_	_		
Study design								
Prospective study	9	1.22	1.07-1.40	0.004	78.7	0.000		
Retrospective study	2	1.52	1.17-1.98	0.002	0.0	0.832		
Dental status								
Self-reported	4	1.15	1.09-1.22	< 0.001	0.0	0.502		
Dental examination	7	1.38	1.00-1.90	0.051	83.1	0.000		
Follow-up (years)								
≥ 10	6	1.11	1.03-1.19	0.005	14.4	0.322		
<10	5	1.43	1.15-1.78	0.001	86.3	0.000		
Adjust for smoking								
Yes	7	1.13	1.07-1.21	< 0.001	7.7	0.369		
No	4	1.47	1.07-2.01	0.016	90.3	0.000		
Prostate cancer								
Study population								
North America	3	1.03	0.89-1.18	0.728	36.9	0.205		
Asia	1	1.14	0.99-1.31	0.065	-	-		
Europe	3	1.73	1.39-2.16	< 0.001	39.8	0.190		
Study design								
Prospective study	7	1.26	1.03-1.54		72.9	0.001		
Dental status								
Self-reported	3	1.12	0.86-1.47	0.395	70.6	0.034		
Dental examination	4	1.44	1.02-2.02	0.036	77.1	0.004		
Follow-up (years)								
≥ 10	6	1.16	0.97-1.38	0.100	60.8	0.026		
<10	1	1.84	1.36-2.49	< 0.001	_	_		
Adjust for smoking								
Yes	5	1.11	1.01-1.22	0.035	43.7	0.130		
No	2	1.95	1.46-2.61	< 0.001	43.8	0.182		
Lung & bronchus cancer								
Study population								
North America	8	1.34	1.24-1.46	< 0.001	46.9	0.068		
Asia	3	1.18	0.72-1.93	0.502	59.8	0.083		
Europe	3	1.11	0.64-1.95	0.709	77.6	0.004		

Table 2 Subgroup analyses of the association between periodontitis and cancer incidence.

(continued on next page)

Table 2 (continued)

Subgroups	No. of studies		Meta-analys	Heterogeneity		
		HR	95%CI	P-value	I ² (%)	P-value
Study design						
Prospective study	11	1.30	1.10-1.53	0.002	68.5	< 0.001
Retrospective study	3	1.36	1.14-1.63	0.001	34.4	0.218
Dental status						
Self-reported	6	1.31	1.21-1.42	< 0.001	0.0	0.635
Dental examination	8	1.33	0.94-1.88	0	75.7	< 0.001
Follow-up (years)						
≥ 10	9	1.28	1.18-1.38	< 0.001	46.5	0.060
<10	5	1.20	0.81-1.77	0.368	78.8	< 0.001
Adjust for smoking						
Yes	10	1.35	1.25-1.46	< 0.001	44.6	0.062
No	4	1.10	0.76-1.59	0.618	69.3	0.011
Colorectal Cancer						
Study population						
North America	7	1.08	0.98-1.19	0.134	18.2	0.291
Asia	4	1.22	0.97-1.55	0.089	91.4	< 0.001
Europe	2	1.10	0.68-1.78	0.686	64.9	0.058
Study design						
Prospective study	11	1.19	0.99-1.43	0.063	81.8	< 0.001
Retrospective study	2	1.24	1.16-1.33	< 0.001	0.0	0.327
Dental status						
Self-reported	8	1.19	1.02-1.39	0.030	87.2	< 0.001
Dental examination	5	1.17	0.92-1.48	0.203	26.4	0.236
Follow-up (years)						
≥10	9	1.21	0.99-1.48	0.065	85.4	< 0.001
<10	4	1.24	1.16-1.33	< 0.001	35.9	0.182
Adjust for smoking						
Yes	10	1.20	1.13-1.26	< 0.001	45.2	0.058
No	3	1.08	0.71-1.63	0.718	90.3	< 0.001
Total cancer						
Study population						
North America	6	1.13	1.09-1.18	< 0.001	0.0	0.965
Asia	3	1.09	0.94-1.27	0.243	92.6	< 0.001
Europe	3	1.18	1.09-1.28	< 0.001	47.1	0.129
Study design						
Prospective study	11	1.15	1.09-1.20	< 0.001	67.1	< 0.001
Retrospective study	1	0.84	0.58-1.19	0.324	_	_
Dental status						
Self-reported	5	1.17	1.12-1.22	< 0.001	57.1	0.054
Dental examination	7	1.08	1.03-1.13	0.001	46.1	0.072
Follow-up (years)						
≥ 10	8	1.11	1.08-1.15	< 0.001	42.1	0.097
_ <10	4	1.22	1.18-1.25	< 0.001	49.0	0.097

(continued on next page)

Table 2 (continued)

Subgroups	No. of studies		Meta-analysis		Meta-analysis Heter		rogeneity
		HR	95%CI	P-value	I ² (%)	P-value	
Adjust for smoking							
Yes	8	1.13	1.09-1.17	< 0.001	0.0	0.803	
No	4	1.18	1.06-1.32	0.002	86.2	< 0.001	

Notes.

CI, confidence interval; HR, hazard ratio.

P = 0.000). Similar to prostrate cancer, we found that periodontal disease increased the risk of lung & bronchus cancer incidence under certain conditions in the North American population, self-reported diagnosis of periodontal disease , follow-up period of more than 10 years, and adjustments for smoking, but the association was not affected by study design type.

Among the 13 studies on periodontal disease and colorectal cancer incidence, seven studies were from North America and showed an HR of 1.08 ($I^2 = 18.2, 95\%$ CI [0.98–1.19], P = 0.134), and five studies in which periodontal disease was diagnosed by dental examination showed an HR of 1.17 ($I^2 = 26.4, 95\%$ CI [0.92–1.48], P = 0.203). We found that periodontal disease increased the risk of colorectal cancer incidence under certain conditions in retrospective study, self-reported diagnosis of periodontal disease , follow-up period of less than 10 years, adjustments for smoking, but the association was not affected by study design type.

Among the 12 studies on periodontal disease and total cancers incidence, three studies were from Asia and showed an HR of 1.09 ($I^2 = 92.6, 95\%$ CI [0.94–1.27], P = 0.243), and eight studies with adjustments for smoking showed an HR of 1.13 ($I^2 = 0, 95\%$ CI [1.09–1.17], P = 0.001). We concluded that periodontal disease increased the risk of total cancer incidence under certain conditions in the North American and European population, prospective study design, but the association was not affected by the diagnostic method for periodontal disease, follow-up period, adjustment for smoking.

Association between periodontitis and cancer mortality

We also analyzed the relationship between periodontal disease and cancer mortality (Fig. 4). A relationship between periodontal disease and total cancer mortality was observed in four studies, and the HR ranged from 1.24 to 1.58; the pooled HR was 1.40, with no heterogeneity ($I^2 = 0$, $P_Q = 0.718$), indicating that the result is reliable. Although the results of current meta-analysis suggest that periodontal disease may increase the risk of breast (HR = 1.25, 95%CI [0.83–1.88], $I^2 = 0.0\%$, $P_Q = 0.809$), prostate (HR = 1.78, 95%CI [0.92–3.46], $I^2 = 0.0\%$, $P_Q = 0.962$), lung & bronchus(HR = 1.48, 95%CI [0.93–2.35], $I^2 = 50.8\%$, $P_Q = 0.154$), colon & rectum (HR = 1.66, 95%CI [0.44–6.27], $I^2 = 76.7\%$, $P_Q = 0.083$) cancer mortality, the overall estimate was not significant because of high levels of uncertainty or moderate heterogeneity. However, we did not perform a subgroup analysis because there were only two studies.

Study, first author (year)	HR (95% CI)	Weight, %
Breast		
Hujoel (2003)	1.32 (0.74, 2.35)	49.70
Heikkilä (2018)	- 1.19 (0.67, 2.12)	50.30
Overall ($I^2 = 0.0\%$, $p_Q = 0.809$)	1.25 (0.83, 1.88)	100.00
Prostate		
Hujoel (2003)	1.81 (0.76, 4.31)	58.05
Heikkilä (2018)	1.75 (0.63, 4.87)	41.95
Overall ($l^2 = 0.0\%$, $p_Q = 0.962$)	1.78 (0.92, 3.46)	100.00
Lung & bronchus		
Hujoel (2003)	1.93 (1.16, 3.21)	44.43
Heikkilä (2018)	1.20 (0.80, 1.80)	55.57
Overall ($I^2 = 50.8\%$, $p_Q = 0.154$)	> 1.48 (0.93, 2.35)	100.00
Colon & rectum		
Hujoel (2003)	0.91 (0.49, 1.69)	56.30
Ahn (2012)	→ 3.58 (1.15, 11.16)	43.70
Overall ($I^2 = 76.7\%$, $p_Q = 0.038$)	1.66 (0.44, 6.27)	100.00
Total cancer		
Hujoel (2003)	1.55 (1.25, 1.92)	31.98
Heikkilä (2018)	1.33 (1.12, 1.58)	49.40
Lu (2019)	1.39 (1.02, 1.89)	15.52
Huang (2020)	1.23 (0.62, 2.45)	3.09
Overall ($l^2 = 0.0\%$, $p_Q = 0.718$)	1.40 (1.24, 1.58)	100.00
	1	
.0896 1	11.2	

Figure 4 Forest plots of the association between periodontitis and cancer mortality. Full-size DOI: 10.7717/peerj.14320/fig-4

Publication bias in meta-analysis

Finally, we performed Begg's and Egger's tests to evaluate publication bias. The results of the two tests are shown in Table 3. We conducted Begg's test in the case of missing items; the P values of the test results after a continuity correction based on Kendall's score in the remaining studies ranged from 0.133-1.000. All the P values were greater than 0.05, indicating that there was no publication bias. We also conducted Egger's test in the case of missing items, the P values of the results of assessing whether the intercept of the remaining items was ranged from 0.147-0.860. All the P values were greater than 0.05, indicating no publication bias. The results of Begg's and Egger's tests were consistent, indicating that there is no publication bias in this meta-analysis.

DISCUSSION

So far, there are a few relevant meta-analyses assessing the association between periodontal disease and breast (*Shi et al., 2018*), prostate (*Wei et al., 2021*), lung (*Wang et al., 2020*),

Publicaton bias (P-value)	Cancer incidence		Cancer	mortality
	Begg's test	Egger's test	Begg's test	Egger's test
Breast cancer	0.640	0.328	1.00	_
Prostate cancer	0.133	0.147	1.00	_
Lung & bronchus cancer	0.767	0.574	1.00	_
Colorectal cancer	0.584	0.357	1.00	_
Total cancer	0.855	0.387	1.00	0.860

Table 3Publication bias in meta-analysis.

and colorectal (*Li et al.*, 2021) cancers. Additionally, there are meta-analyses that have revealed that infections caused by periodontal pathogens increase the risk of total cancers incidence (*Michaud et al.*, 2017) and mortality (*Romandini et al.*, 2021a). However, no one study has described the correlation between periodontal disease and multiple types of cancer in terms of incidence and mortality comprehensively and in detail. Although our results are mostly consistent with those of the previous meta-analyses, our analysis is the most comprehensive because it includes new studies and the latest results, and we reviewed nearly 20 years of reliable research. The sensitivity analysis further proved the accuracy of our results. The subgroup analysis helped us in better analyze the sources of heterogeneity.

On reviewing the 27 studies included in this meta-analysis, we preliminarily found that compared with healthy individuals, patients with periodontal disease were 1.14 times more susceptible to breast cancer, 1.26 times more susceptible to prostate cancers, 1.3 times more susceptible to lung and bronchial cancers, and 1.18 times more susceptible to colorectal cancer. Through a meta-analysis of eight studies, Shi et al. (2018) found that periodontal disease increased the susceptibility to breast cancer (risk ratio [RR] = 1.19,95%CI [1.11–1.26], $I^2 = 17.6\%$, P = 0.30). This result is consistent with ours. Wei et al. (2021) analyzed seven studies, and the results showed that periodontal disease was significantly associated with prostate cancer (RR = 1.17, 95% CI [1.07–1.27], $I^2 = 5.8\%$, P = 0.001); however, the results of the subgroup analysis showed that some of the 95% CIs fell on both sides. After 18 years of follow-up, Hiraki et al. (2008) concluded that periodontal disease did not increase the risk of developing colorectal cancer (HR = 1.06, 95% CI [0.91–1.24]). Based on a analysis of three cohort studies, Ren et al. (2016) also came to a conclusion that there is no relationship between oral health and colorectal cancer. By contrast, one study reported that women with moderate or severe periodontal disease were at a higher risk of colorectal cancer; there were no adjustments for smoking status, body mass index, or alcohol consumption (Momen-Heravi et al., 2017). Another study (Lee et al., 2018) found that periodontitis increased the risk of colorectal cancer among male patients, former or current smokers, and patients with an alcohol intake above the moderate level. Similarly, the association between periodontal disease and lung cancer is very controversial. Wang et al. (2020) analyzed six high-quality studies and found that periodontal disease greatly increased the risk of lung cancer (HR = 1.40, 95% CI [1.25–1.58], $I^2 = 8.7\%$). Two studies (Michaud et al., 2008; Hiraki et al., 2008) also obtained the same result after adjustments for smoking-related variables, but they obtained the opposite result when they analyzed

patients who never smoked cigarettes, but were pipe or cigar smokers. *Xiao et al.* (2020) found that periodontal bacterial infection increased the incidence of total cancer (OR = 1.25, 95% CI [1.03–1.52], $I^2 = 71\%$, P = 0.02), but the results of the subgroup analysis showed that some of the 95% CIs fell on both sides.

This meta-analysis also concluded that there is a clear correlation between periodontal disease and total cancer mortality. Patients with periodontal disease have a 1.4 times higher risk of dying from total cancer than those without periodontal disease. *Romandini et al.* (2021b) reviewed 57 studies and concluded that periodontal disease increased the risk of all-cause mortality, including cancer mortality (RR = 1.38, 95% CI [1.24–1.53], $I^2 = 29.8\%$, P < 0.001), which is consistent with our result.

We found that the correlation between periodontal disease and breast cancer incidence was maintained after the subgroup analysis. While performing the meta-analysis, we found greater heterogeneity in the included studies; subsequently, we performed a subgroup analysis of factors, such as study population, study design, dental status, follow-up period, and adjustments for smoking, which might affect heterogeneity. First, we found that, compared with studies from countries in Europe and Asia, those from North America were less heterogeneous. Second, prospective studies were more heterogeneous. In fact, the two study designs have their own advantages and disadvantages. It is recommended to adopt a prospective follow-up study design if the purpose of a study is to evaluate the effect of a certain treatment method. It is recommended to choose a retrospective follow-up study design if the purpose of a study is to explore and explain a certain phenomenon (Vandenbroucke, 2008). The advantage of the prospective design is the accuracy of data including exposures, confounding factors, and endpoints, but these studies require a lot of time and financial resources. The merit of retrospective studies is the time saved by the direct use of existing data, but these studies are susceptible to selection bias. The limitation of retrospective studies is that it is not possible to establish causal effects. The results may be influenced by confounding factors expect to the exposure factors, which are often not accurately measured or may even be unknown (Euser et al., 2009). Third, the heterogeneity of the studies, which was observed over a period of 10 years, was relatively low, indicating that the results obtained from the studies with long follow-up periods are relatively accurate and consistent. In the subgroup analysis, six studies with follow-up periods of over 10 years demonstrated a 1.11-fold increase in breast cancer risk, with low heterogeneity ($I^2 = 14.4\%$). Among the eight studies included in Tingting's meta-analysis (Shi et al., 2018), five studies had a follow-up period of more than 10 years and revealed a 1.38-fold increase in breast cancer risk through a subgroup analysis with minimal heterogeneity ($I^2 = 7.0\%$). Fourth, among the studies we included, the diagnosis of periodontal disease was self-reported in nine. In many of the previous studies, the diagnosis of periodontal disease was based on self-reported patient data or administrative data. Although this approach may sound unreliable, it can save time. In addition, the manpower and financial resources required for a periodontal examination can be saved. Moreover, self-reported diagnosis of periodontal disease has been proven to be acceptable, with a diagnostic OR of 1.4 (95% CI [0.9–2.2]) for the question on bleeding gums and

of 11.7 (95% CI [4.1–33.4]) for the question on tooth mobility, it was also found to be suitable in large-scale epidemiological studies (*Abbood et al.*, 2016).

Smoking is a risk factor of many diseases. A previous study has confirmed that smoking is an independent risk factor for periodontal and respiratory diseases, including lung cancer(OR=2.12, 95% CI [1.32–3.42]) (*Waziry et al., 2017*). Therefore, smoking should be excluded as an confounding factor in an analysis of the association between periodontal disease and lung cancer. Of the 27 studies included in this meta-analysis, adjustments for smoking were performed in 18 studies, and 10 of the 14 studies on periodontitis and lung cancer involved adjustments for smoking. The probability of the development of lung and bronchial cancer in patients with periodontal disease was 1.35 times higher than that in individuals with healthy periodontal tissues, but the statistical heterogeneity was great. In the review by *Michaud et al. (2017)*, based on five studies after adjustments for smoking, positive association was found between periodontal disease and lung cancer, with a pooled RR of 1.33 (95% CI [1.19–1.49], $I^2 = 0\%$, P = 0.58), this is consistent with our conclusion, and the values are close to ours. In a prospective study by *Tai et al. (2019)*, smoking was not excluded as a disincentive, therefore, the polled HR (HR = 1.9, 95% CI [1.08–3.35], P = 0.0267) was significantly higher than ours.

There are several limitations in this meta-analysis. First, although most confounding factors were adjusted for in the included studies, few studies adjusted for other oral health problems and stress, which may affect the results of these studies. Second, genetic factors play a very important role in the occurrence of cancer. While diagnosing the patients' condition, few researchers noted whether they had family history of cancer, therefore, this important influencing factor was most likely ignored in the data analysis, which would also affect the final results.

CONCLUSIONS

This meta-analysis revealed that periodontal disease is significantly associated with the risk of the incidence of breast cancer and that periodontal disease may increase the risk of total cancer mortality. Our results prompt the general public to pay attention to periodontal health and to receive periodontal treatment in a regular and timely manner. In conclusion, our results suggest that patients with periodontal disease should pay special attention to breast cancer screening during regular general health examinations. Apart from breast ultrasound, a mammography examination conducted once every 1–2 years would be helpful for the early detection and early treatment of breast cancer. Of course, attention should also be paid to other related cancers, such as lung, colorectal, and prostate cancers. However, well-designed studies, populations from diverse geographic regions, and adjustments for exact confounding factors are needed to confirm our findings and to further explore the relationship between periodontal disease and cancers incidence and mortality.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Kaili Wang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Zheng Zhang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Zuomin Wang conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability: The raw measurements are available in the Supplementary Files.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.14320#supplemental-information.

REFERENCES

- Abbood HM, Hinz J, Cherukara G, Macfarlane TV. 2016. Validity of self-reported periodontal disease: a systematic review and meta-analysis. *Journal of Periodontology* 87(12):1474–1483 DOI 10.1902/jop.2016.160196.
- Ahn J, Segers S, Hayes RB. 2012. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality. *Carcinogenesis* 33(5):1055–1058 DOI 10.1093/carcin/bgs112.
- Arora M, Weuve J, Fall K, Pedersen NL, Mucci LA. 2010. An exploration of shared genetic risk factors between periodontal disease and cancers: a prospective co-twin study. *American Journal of Epidemiology* 171(2):253–259 DOI 10.1093/aje/kwp340.
- Cao M, Li H, Sun D, Chen W. 2020. Cancer burden of major cancers in China: a need for sustainable actions. *Cancer Communications* 40(5):205–210 DOI 10.1002/cac2.12025.
- **Chou SH, Tung YC, Wu LS, Chang CJ, Kung S, Chu PH. 2018.** Severity of chronic periodontitis and risk of gastrointestinal cancers: a population-based follow-up study from Taiwan. *Medicine* **97(27)**:e11386.
- Chrysanthakopoulos NA. 2016. Correlation between periodontal disease indices and lung cancer in Greek adults: a case-control study. *Experimental Oncology* **38(1)**:49–53 DOI 10.31768/2312-8852.2016.38(1):49-53.

- **Chung SD, Tsai MC, Huang CC, Kao LT, Chen CH. 2016.** A population-based study on the associations between chronic periodontitis and the risk of cancer. *International Journal of Clinical Oncology* **21**(2):219–223 DOI 10.1007/s10147-015-0884-6.
- Dizdar O, Hayran M, Guven DC, Yılmaz TB, Taheri S, Akman AC, Bilgin E, Hüseyin B, Berker E. 2017. Increased cancer risk in patients with periodontitis. *Current Medical Research and Opinion* 33(12):2195–2200 DOI 10.1080/03007995.2017.1354829.
- Eke PI, Thornton-Evans GO, Wei L, Borgnakke WS, Dye BA, Genco RJ. 2018. Periodontitis in US adults: national health and nutrition examination survey 2009-2014. *Journal of the American Dental Association* **149(7)**:576–588 DOI 10.1016/j.adaj.2018.04.023.
- Eliot MN, Michaud DS, Langevin SM, McClean MD, Kelsey KT. 2013. Periodontal disease and mouthwash use are risk factors for head and neck squamous cell carcinoma. *Cancer Causes Control* 24(7):1315–1322 DOI 10.1007/s10552-013-0209-x.
- Euser AM, Zoccali C, Jager KJ, Dekker FW. 2009. Cohort studies: prospective versus retrospective. *Nephron Clinical Practice* 113(3):c214–c217 DOI 10.1159/000235241.
- Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R, Miller G, Ravel J, Hayes RB, Ahn J. 2018. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. *Gut* 67(1):120–127 DOI 10.1136/gutjnl-2016-312580.
- Freudenheim JL, Genco RJ, LaMonte MJ, Millen AE, Hovey KM, Mai X, Nwizu N, Andrews CA, Wactawski-Wende J. 2016. Periodontal disease and breast cancer: prospective cohort study of postmenopausal women. *Cancer Epidemiology, Biomarkers & Prevention* 25(1):43–50 DOI 10.1158/1055-9965.EPI-15-0750.
- Genco RJ, Borgnakke WS. 2020. Diabetes as a potential risk for periodontitis: association studies. *Periodontology 2000* 83(1):40–45 DOI 10.1111/prd.12270.
- Gopinath D, Kunnath Menon R, Veettil SK, George Botelho M, Johnson NW. 2020. Periodontal diseases as putative risk factors for head and neck cancer: systematic review and meta-analysis. *Cancers* 12(7):1893 DOI 10.3390/cancers12071893.
- Güven DC, Dizdar Ö, Akman AC, Berker E, Yekedüz E, Ceylan F, Başpınar B, Akbıyık I, Aktaş BY, Yüce D, Erman M, Hayran M. 2019. Evaluation of cancer risk in patients with periodontal diseases. *Turkish Journal Of Medical Sciences* **49**(3):826–831 DOI 10.3906/sag-1812-8.
- Han MA. 2017. Oral health status and behavior among cancer survivors in Korea Using Nationwide Survey. *International Journal of Environmental Research and Public Health* 15(1):14 DOI 10.3390/ijerph15010014.
- Heikkilä P, But A, Sorsa T, Haukka J. 2018. Periodontitis and cancer mortality: registerbased cohort study of 68,273 adults in 10-year follow-up. *International Journal of Cancer* 142(11):2244–2253 DOI 10.1002/ijc.31254.
- Hiraki A, Matsuo K, Suzuki T, Kawase T, Tajima K. 2008. Teeth loss and risk of cancer at 14 common sites in Japanese. *Cancer Epidemiology, Biomarkers & Prevention* 17:1222–1227 DOI 10.1158/1055-9965.EPI-07-2761.
- Hu JM, Shen CJ, Chou YC, Hung CF, Tian YF, You SL, Chen CY, Hsu CH, Hsiao CW, Lin CY, Sun CA. 2018. Risk of colorectal cancer in patients with periodontal disease

severity: a nationwide, population-based cohort study. *International Journal of Colorectal Disease* **33(3)**:349–352 DOI 10.1007/s00384-018-2965-2.

- Huang Y, Michaud DS, Lu J, Platz EA. 2020. The association of clinically determined periodontal disease and edentulism with total cancer mortality: The National Health and Nutrition Examination Survey III. *International Journal of Cancer* 147(6):1587–1596 DOI 10.1002/ijc.32941.
- Hujoel PP, Drangsholt M, Spiekerman C, Weiss NS. 2003. An exploration of the periodontitis-cancer association. *Annals of Epidemiology* 13(5):312–316 DOI 10.1016/S1047-2797(02)00425-8.
- Ilhan D, Oktay I, Nur B, Fisekcioglu E, Lim S, Lepkowski JM, Ismail AI. 2017. Percentage and severity of periodontal diseases in Turkish adults aged 35+ years, 2009-10. *Journal of Public Health Dentistry* 77(4):325–333 DOI 10.1111/jphd.12211.
- Lee D, Jung KU, Kim HO, Kim H, Chun HK. 2018. Association between oral health and colorectal adenoma in a screening population. *Medicine* 97(37):e12244 DOI 10.1097/MD.00000000012244.
- Lee JH, Kweon HH, Choi JK, Kim YT, Choi SH. 2017. Association between periodontal disease and prostate cancer: results of a 12-year longitudinal Cohort Study in South Korea. *Journal of Cancer* 8(15):2959–2965 DOI 10.7150/jca.20532.
- Li W, Xu J, Zhang R, Li Y, Wang J, Zhang X, Lin L. 2021. Is periodontal disease a risk indicator for colorectal cancer? A systematic review and meta-analysis. *Journal of Clinical Periodontology* **48(3)**:336–347 DOI 10.1111/jcpe.13402.
- Liccardo D, Marzano F, Carraturo F, Guida M, Femminella GD, Bencivenga L, Agrimi J, Addonizio A, Melino I, Valletta A, Rengo C, Ferrara N, Rengo G, Cannavo A.
 2020. Potential bidirectional relationship between periodontitis and Alzheimer's disease. *Frontiers in Physiology* 11:683 DOI 10.3389/fphys.2020.00683.
- Lu J, Zaimi I, Barber JR, Joshu CE, Prizment AE, Beck JD, Platz EA, Michaud DS. 2019. SES and correlated factors do not explain the association between periodontal disease, edentulism, and cancer risk. *Annals of Epidemiology* 38:35–41 DOI 10.1016/j.annepidem.2019.08.005.
- Mai X, LaMonte MJ, Hovey KM, Freudenheim JL, Andrews CA, Genco RJ, Wactawski-Wende J. 2016. Periodontal disease severity and cancer risk in postmenopausal women: the Buffalo OsteoPerio study. *Cancer Causes Control* 27(2):217–228 DOI 10.1007/s10552-015-0699-9.
- Mai X, LaMonte MJ, Hovey KM, Nwizu N, Freudenheim JL, Tezal M, Scannapieco F, Hyl A, Andrews CA, Genco RJ, Wactawski-Wende J. 2014. History of periodontal disease diagnosis and lung cancer incidence in the Women's Health Initiative Observational Study. *Cancer Causes Control* **25(8)**:1045–1053 DOI 10.1007/s10552-014-0405-3.
- Malinowski B, Węsierska A, Zalewska K, Sokołowska MM, Bursiewicz W, Socha M, Ozorowski M, Pawlak-Osińska K, Wiciński M. 2019. The role of *Tannerella forsythia* and *Porphyromonas gingivalis* in pathogenesis of esophageal cancer. *Infectious Agents and Cancer* 14:3 DOI 10.1186/s13027-019-0220-2.
- Michaud DS, Fu Z, Shi J, Chung M. 2017. Periodontal disease, tooth loss, and cancer risk. *Epidemiologic Reviews* **39**(1):49–58 DOI 10.1093/epirev/mxx006.

- Michaud DS, Kelsey KT, Papathanasiou E, Genco CA, Giovannucci E. 2016. Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the Health Professionals Follow-up Study. *Annals of Oncology* 27(5):941–947 DOI 10.1093/annonc/mdw028.
- Michaud DS, Liu Y, Meyer M, Giovannucci E, Joshipura K. 2008. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. *The Lancet Oncology* **9(6)**:550–558 DOI 10.1016/S1470-2045(08)70106-2.
- Michaud DS, Lu J, Peacock-Villada AY, Barber JR, Joshu CE, Prizment AE, Beck JD, Offenbacher S, Platz EA. 2018. Periodontal disease assessed using clinical dental measurements and cancer risk in the ARIC study. *Journal of the National Cancer Institute* 10(8):843–854.
- Molon RS, Rossa Jr C, Thurlings RM, Cirelli JA, Koenders MI. 2019. Linkage of periodontitis and rheumatoid arthritis: current evidence and potential biological interactions. *International Journal of Molecular Sciences* 20(18):4541 DOI 10.3390/ijms20184541.
- Momen-Heravi F, Babic A, Tworoger SS, Zhang L, Wu K, Smith-Warner SA, Ogino S, Chan AT, Meyerhardt J, Giovannucci E, Fuchs C, Cho E, Michaud DS, Stampfer MJ, Yu YH, Kim D, Zhang X. 2017. Periodontal disease, tooth loss and colorectal cancer risk: results from the Nurses' Health Study. *International Journal of Cancer* 140(3):646–652 DOI 10.1002/ijc.30486.
- Nascimento GG, Gastal MT, Leite FRM, Quevedo LA, Peres KG, Peres MA, Horta BL, Barros FC, Demarco FF. 2019. Is there an association between depression and periodontitis? A birth cohort study. *Journal of Clinical Periodontology* **46**(1):31–39.
- Nwizu NN, Marshall JR, Moysich K, Genco RJ, Hovey KM, Mai X, LaMonte MJ, Freudenheim JL, Wactawski-Wende J. 2017. Periodontal disease and incident cancer risk among postmenopausal women: results from the women's health initiative observational Cohort. *Cancer Epidemiology, Biomarkers & Prevention* 26(8):1255–1265 DOI 10.1158/1055-9965.EPI-17-0212.
- Ren HG, Luu HN, Cai H, Xiang YB, Steinwandel M, Gao YT, Hargreaves M, Zheng W, Blot WJ, Long JR, Shu XO. 2016. Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis. *Annals of Oncology* 27(7):1329–1336 DOI 10.1093/annonc/mdw172.
- Romandini M, Baima G, Antonoglou G, Bueno J, Figuero E, Sanz M. 2021a. Periodontitis, edentulism, and risk of mortality: a systematic review with meta-analyses. *Journal* of Dental Research 100(1):37–49 DOI 10.1177/0022034520952401.
- Romandini M, Baima G, Antonoglou G, Bueno J, Figuero E, Sanz M. 2021b. Periodontitis, edentulism, and risk of mortality: a systematic review with meta-analyses. *Journal* of Dental Research 100(1):37–49 DOI 10.1177/0022034520952401.
- Sanz M, Del Castillo AM, Jepsen S, Gonzalez-Juanatey JR, D'Aiuto F, Bouchard P, Chapple I, Dietrich T, Gotsman I, Graziani F, Herrera D, Loos B, Madianos P, Michel JB, Perel P, Pieske B, Shapira L, Shechter M, Tonetti M, Vlachopoulos C, Wimmer G. 2020. Periodontitis and cardiovascular diseases, consensus report. *Global Heart* 15(1):1 DOI 10.5334/gh.400.

- Sfreddo CS, Maier J, De David SC, Susin C, Moreira CHC. 2017. Periodontitis and breast cancer: a case-control study. *Community Dentistry and Oral Epidemiology* 45(6):545–551 DOI 10.1111/cdoe.12318.
- Shi T, Min M, Sun C, Zhang Y, Liang M, Sun Y. 2018. Periodontal disease and susceptibility to breast cancer: a meta-analysis of observational studies. *Journal of Clinical Periodontology* 45(9):1025–1033 DOI 10.1111/jcpe.12982.
- Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA: A Cancer Journal for *Clinicians* 69(1):7–34 DOI 10.3322/caac.21551.
- Sun HY, Jiang H, Du MQ, Wang X, Feng XP, Hu Y, Lin HC, Wang B, Si Y, Wang CX, Zheng SG, Liu XN, Rong WS, Wan WJ, Tai BJ. 2018. The prevalence and associated factors of periodontal disease among 35 to 44-year-old Chinese adults in the 4th National Oral Health Survey. *Chinese Journal of Dental Research* 21(4):241–247.
- Tai SH, Chen JP, Chang HS, Kuo HC. 2019. Periodontitis as a risk factor for lung cancer among women: a nationwide matched cohort study. *The Kaohsiung Journal of Medical Sciences* 35(2):123–124 DOI 10.1002/kjm2.12018.
- Takeuchi K, Matsumoto K, Furuta M, Fukuyama S, Takeshita T, Ogata H, Suma S, Shibata Y, Shimazaki Y, Hata J, Ninomiya T, Nakanishi Y, Inoue H, Yamashita Y.
 2019. Periodontitis is associated with chronic obstructive pulmonary disease. *Journal* of Dental Research 98(5):534–540 DOI 10.1177/0022034519833630.
- **Vandenbroucke JP. 2008.** Observational research, randomised trials, and two views of medical science. *PLOS Medicine* **5**(**3**):e67 DOI 10.1371/journal.pmed.0050067.
- Wang J, Yang X, Zou X, Zhang Y, Wang J, Wang Y. 2020. Relationship between periodontal disease and lung cancer: a systematic review and meta-analysis. *Journal of Periodontal Research* 55(5):581–593 DOI 10.1111/jre.12772.
- Waziry R, Jawad M, Ballout RA, Akel MAl, Akl EA. 2017. The effects of waterpipe tobacco smoking on health outcomes: an updated systematic review and meta-analysis. *International Journal of Epidemiology* **46**(1):32–43.
- Wei Y, Zhong Y, Wang Y, Huang R. 2021. Association between periodontal disease and prostate cancer: a systematic review and meta-analysis. *Medicina Oral, Patologia Oral y Cirugia Bucal* 26(4):e459-e465.
- Wen BW, Tsai CS, Lin CL, Chang YJ, Lee CF, Hsu CH, Kao CH. 2014. Cancer risk among gingivitis and periodontitis patients: a nationwide cohort study. *QJM* 107(4):283–290 DOI 10.1093/qjmed/hct248.
- Xiao L, Zhang Q, Peng Y, Wang D, Liu Y. 2020. The effect of periodontal bacteria infection on incidence and prognosis of cancer: a systematic review and metaanalysis. *Medicine* **99**(15):e19698.
- Yao QW, Zhou DS, Peng HJ, Ji P, Liu DS. 2014. Association of periodontal disease with oral cancer: a meta-analysis. *Tumor Biology* **35**(7):7073–7077 DOI 10.1007/s13277-014-1951-8.
- Yoon HS, Wen W, Long J, Zheng W, Blot WJ, Cai Q. 2019. Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States. *Lung Cancer* 127:90–95 DOI 10.1016/j.lungcan.2018.11.028.